CONJUGADO ANTICORPO ANTI-PDL1-FÁRMACO E USO DO MESMO

The antibody-drug conjugate with a novel structure targets PDL1-positive tumor cells with enhanced potency and reduced toxicity, addressing the limitations of current anti-PDL1 monoclonal antibodies by improving tumor targeting and reducing side effects.

BR112025024274A2Pending Publication Date: 2026-11-10SHANGHAI HENLIUS BIOTECH INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024274
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-10
Filing Date
2024-05-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current anti-PDL1 monoclonal antibodies have limited clinical efficacy due to low permeability in dense tumors and systemic side effects, necessitating the development of more biologically active and less toxic antibody-drug conjugates that target PDL1.

Method used

An antibody-drug conjugate with a structure of formula (I): TP-[L1-L2-L3-D]k, where TP selectively binds to PDL1, L1 is an extension unit, L2 is an amino acid residue or short peptide, L3 is a spacer element, and D is a biologically active molecule, with a drug-to-antibody ratio between 0.1 and 10.0, enhancing tumor targeting and reducing toxicity.

Benefits of technology

The conjugate exhibits improved potency and antitumor activity with lower toxicity, effectively targeting and destroying PDL1-positive tumor cells, including resistant mutants, and demonstrating a bystander effect.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

An antibody-drug conjugate (ADC) and a use thereof. The present invention relates to a novel anti-PDL1 ADC and a method and use thereof for treating diseases or conditions related to PDL1 expression.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 89 Anti-PDL1 Antibody Conjugate - Drug and its Use

[0001] This application claims priority over Chinese patent application No. CN 202310513959.4, filed on May 9, 2023, and Chinese patent application No. CN 202311311898.X, filed on October 10, 2023. Technical field

[0002] This application pertains to the pharmaceutical field and relates to an antibody-drug conjugate (ADC) and its use. In particular, this application relates to a novel anti-PDL1 antibody-drug conjugate, a method of using it, and its use in the treatment of diseases or disorders related to PDL1 expression. Background of the art

[0003] In recent decades, antibodies against PD-1 and PDL1, representative of immune checkpoint inhibitors, have promoted the rapid development of tumor immunotherapy and have become another effective therapeutic means for tumors after surgery, radiotherapy, chemotherapy, and targeted therapy. However, due to the heterogeneity of tumors and the complexity of the regulatory mechanisms of PDL1 expression, as well as the relatively low permeability of macromolecular anti-PDL1 monoclonal antibodies to dense tumors, the clinical use of anti-PDL1 monoclonal antibodies is quite limited, and the overall objective response rate in patients is around 15% to 30%. There is a significant unmet clinical need.

[0004] To improve responsiveness and therapeutic efficacy in patients with tumors, exploration has begun of combining anti-PD-1 monoclonal antibodies with chemotherapy, targeted therapy, and radiotherapy, especially radiotherapy. Since chemotherapy can cause immunogenic cell death, more tumor antigens can be released, effectively promoting the activation of the immune response. Furthermore, the number and activity of immunosuppressive cells can also be reduced. Consequently, chemotherapy is the main alternative solution to combinations of immunizations. However, the systemic side effects caused by Petition 870250101969, dated 07 / 11 / 2025, page 9 / 312 2 / 89 Chemotherapy remains a very complicated problem. PDL1 is expressed in several types of tumors and has limited expression in normal tissues. Therefore, the conjugation of highly active small cytotoxic chemical drugs with anti-PDL1 monoclonal antibodies may result in bifunctional ADC drugs targeting PDL1, and this will be a very promising direction in terms of drug development.

[0005] Currently, there are PDL1-targeted ADC drugs in exploratory preclinical and phase I trials. SGN-PDL1V is a classic technical product of a PDL1-targeted ADC platform, developed by Seagen, using MMAE as the loaded drug (payload), and is currently in phase I clinical trials. MMAE (monomethylauristatin E), one of the most widely used loaded drugs in ADCs, kills cancer cells primarily by inhibiting tubulin polymerization, which is effective in mitotic inhibition; however, the ADC product has a relatively narrow quality window. Consequently, there is an urgent need in the art for drugs that are more biologically active and less toxic, especially drugs that are effective against resistant mutants, for example antibody-drug conjugates, in order to further improve efficacy and reduce side effects. Summary of the invention

[0006] This application relates to an antibody-drug conjugate of formula (I) as defined herein and to a pharmaceutical composition comprising the antibody-drug conjugate. This application is characterized by a method for treating or preventing a tumor or cancer related to PDL1 expression, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody-drug conjugate of formula (I), prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, as defined herein. The method of this application may be used to treat or prevent a tumor or Petition 870250101969, dated 07 / 11 / 2025, page 10 / 312 3 / 89 cancer related to PD-L1 expression.

[0007] A first aspect of the present application relates to an antibody-drug conjugate, a prodrug, a pharmaceutically acceptable salt or a solvate thereof, or a solvate of the pharmaceutically acceptable salt, wherein the antibody-drug conjugate has a structure of formula (I): TP-[L1-L2-L3-D]k (I) where TP is a targeting fraction that selectively binds to or recognizes PDL1; L1 is an extension unit that connects TP and L2; L2 is an optional amino acid residue or a short peptide consisting of 2 to 10 amino acid residues; L3 is a spacer element; D is a biologically active molecule; ek represents any numerical value between approximately 0.1 and approximately 10.0.

[0008] Another aspect of the present application relates to a pharmaceutical composition comprising the antibody-drug conjugate of formula (I), the prodrug, the pharmaceutically acceptable salt or solvate thereof, or the solvate of the pharmaceutically acceptable salt and optionally a pharmaceutically acceptable vehicle, diluent or excipient.

[0009] Another aspect of the present application relates to a method for treating a tumor or cancer related to PDL1 expression. The method comprises administering to a subject in need thereof, the antibody-drug conjugate of formula (I), a prodrug, a pharmaceutically acceptable salt or solvate thereof, or a solvate of the pharmaceutically acceptable salt, or a pharmaceutical composition comprising the same. The tumor or cancer related to PDL1 expression is selected from melanoma, lung cancer (e.g., non-small cell lung cancer or small cell lung cancer), head and neck cancer, breast cancer Petition 870250101969, dated 07 / 11 / 2025, page 11 / 312 4 / 89 (for example, triple-negative breast cancer (TNBC)), ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, bladder cancer, esophageal cancer, kidney cancer, prostate cancer, pancreatic cancer, and glioma.

[0010] Another aspect of the present application relates to the use of the antibody-drug conjugate of formula (I), prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, or pharmaceutical composition comprising the same in the preparation of a medicament.

[0011] In particular, the present application also provides an antibody-drug conjugate and a composition with improved potency and / or antitumor activity and lower toxicity compared with known anti-PDL1 ADCs in the prior art.

[0012] The details of the present application are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present application, illustrative methods and materials are described herein. Other features, objects and advantages of the present application will be evident from the description and claims. In the description and accompanying claims, singular forms also include plural forms, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by those with common skill in the field to which the present application pertains. All patents and publications cited in the description are incorporated herein by reference in their entirety.

[0013] The content of all references (including bibliographic references, granted patents, published patent applications and copending patent applications) cited throughout this application is expressly incorporated herein by reference in its entirety. Unless otherwise defined, all technical and scientific terms used in this document Petition 870250101969, dated 07 / 11 / 2025, p. 12 / 312 5 / 89 have the meanings as usually understood by those with common skill in the technique. Brief description of the drawings

[0014] FIG. 1 is a graph showing the affinity of an anti-PDL1 antibody-drug conjugate for PDL1-positive NCI-H292 and NCI-H441 cells. (A) (A) Affinity of the anti-PDL1 antibody-drug conjugate MAB20-LP62 (DAR8) for NCI-H292 cells. (B) Affinity of the anti-PDL1 antibody-drug conjugate MAB20-LP62 (DAR8) by NCI-H441 cells. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62 (whose structure is shown in the Examples); DAR represents the loaded drug:antibody ratio; IgG1 represents a human IgG1 isotype control, κ.

[0015] FIG. 2 is a graph showing the internalization of the anti-PDL1 antibody-drug conjugate in PDL1-positive NCI-H292 cells over time. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; DAR represents the loaded drug:antibody ratio.

[0016] FIG. 3 is a graph showing the cell death activity of the anti-PDL1 antibody-drug conjugate MAB20-LP62 (DAR8). (A) Cell death activity of MAB20-LP62 (DAR8) in an NCI-H292 cell line. (B) Cell death activity of MAB20-LP62 (DAR8) in a BXPC3 cell line. (C) Cell death activity of MAB20-LP62 (DAR8) in an NCI-H441 cell line. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; DAR represents the loaded drug:antibody ratio.

[0017] FIG. 4 is a graph showing the cross-linking activity of the anti-PDL1 antibody-drug conjugate to PDL1s derived from different Petition 870250101969, dated 07 / 11 / 2025, page 13 / 312 6 / 89 species. (A) Binding of MAB20-LP62 (DAR8) to the ECD of human PDL1. (B) Binding of MAB20-LP62 (DAR8) to the ECD of cynomolgus PDL1. (C) Binding of MAB20-LP62 (DAR8) to the ECD of mouse PDL1. (D) Binding of MAB20-LP62 (DAR8) to the ECD of rat PDL1. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; DAR represents the loaded drug:antibody ratio; IgG1 represents a human IgG1 isotype control, κ.

[0018] FIG. 5 is a graph showing the bystander effect of the anti-PDL1 antibody-drug conjugate MAB20-LP62 (DAR8). (A) In vitro killing of MDA-MB-468 cells by the test molecules. (B) Bystander killing of MDAMB-468 cells by a supernatant of a medium with PD-L1 overexpressing HEK293 cells incubated with the test molecules. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; IgG1-LP62 represents an antibody-drug conjugate formed by conjugating IgG1 to LP62, with a DAR value of 8; DAR represents the loaded drug:antibody ratio.

[0019] FIG. 6 is a graph showing the in vitro killing of human macrophages by the anti-PDL1 antibody-drug conjugate MAB20-LP62 (DAR8). Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; IgG1-LP62 represents an antibody-drug conjugate formed by conjugating IgG1 to LP62; IgG1-VCMMAE represents an antibody-drug conjugate formed from an IgG1 isotype control prepared similarly to Example 3.2 with MC-VC-PABC-MMAE; SGN-PDL1V represents a reference ADC molecule as described in WO 2021067776 A1, which is an antibody-drug conjugate formed by conjugating an antibody fraction of SGNPDL1V (whose amino acid sequence is shown in the Sequence Listing). Petition 870250101969, dated 07 / 11 / 2025, page 14 / 312 7 / 89 to a toxin-binding molecule MC-VC-PABC-MMAE; and DAR represents the ratio of drug loaded to antibody.

[0020] FIG. 7 is a graph showing the death of human dendritic cells in vitro by the anti-PDL1 antibody-drug conjugate MAB20-LP62 (DAR8). Note: MAB20 represents an anti-PDL1 antibody, whose amino acid sequence is presented in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; IgG1-VC-MMAE represents an antibody-drug conjugate formed from an IgG1 isotype control prepared similarly to Example 3.2 with MC-VCPABC-MMAE; SGN-PDL1V represents a reference ADC molecule as described in WO 2021067776 A1, which is an antibody-drug conjugate formed by conjugating an antibody moiety of SGN-PDL1V (whose amino acid sequence is shown in the Sequence Listing) to an MC-VC-PABC-MMAE toxin linker; and DAR represents the loaded drug:antibody ratio.

[0021] FIG. 8 is a graph showing the antitumor activity of the anti-PDL1 antibody-drug conjugate in a model of NCG mice subcutaneously inoculated with the MDA-MB-231 human breast cancer cell line. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is presented in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; MAB20-VC-MMAE represents an antibody-drug conjugate formed by conjugating MAB20 to the MC-VC-PABC-MMAE toxin-linker; MAB20-GGFGDxd represents an antibody-drug conjugate formed by conjugating MAB20 to the MC-GGFG-Dxd toxin-linker; A 1.3 represents the A 1.3 toxin compound of Example 1, which is a free charged drug; DAR represents the ratio of drug carried to antibody.

[0022] FIG. 9 is a graph showing the antitumor activity of the anti-PDL1 antibody-drug conjugate in an NCG mouse model inoculated subcutaneously with the human pancreatic cancer cell line BxPC3. Petition 870250101969, dated 07 / 11 / 2025, page 15 / 312 8 / 89 Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; MAB20-VC-MMAE represents an antibody-drug conjugate formed by conjugating MAB20 to the toxin-linker MC-VC-PABC-MMAE; MAB20-GGFGDXD represents an antibody-drug conjugate formed by conjugating MAB20 to the toxin-linker MC-GGFG-DXD; A 1.3 represents the toxin compound A 1.3 from Example 1, which is a free charged drug; DAR represents the charged drug:antibody ratio.

[0023] FIG. 10 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LU6437 xenografted BALB / c nude mice with human non-small cell lung cancer. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; SGN-PDL1V represents a reference ADC molecule as described in WO 2021067776 A1, which is an antibody-drug conjugate formed by conjugating an antibody fraction of SGN-PDL1V (whose amino acid sequence is shown in the Sequence Listing) to an MC-VC-PABC-MMAE toxin linker; and DAR represents the loaded drug:antibody ratio.

[0024] FIG. 11 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LD10011-200617 xenografted NU / NU mice with human PD-L1-positive liver cancer. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; DAR represents the loaded drug:antibody ratio.

[0025] FIG. 12 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LD1-2023-411020 xenografted NCG naked mice with PD-L1-positive squamous cell carcinoma of the head and neck. Petition 870250101969, dated 07 / 11 / 2025, page 16 / 312 9 / 89 human. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; A 1.3 represents the toxin A 1.3 compound from Example 1, which is a free charged drug; DAR represents the charged drug:antibody ratio.

[0026] FIG. 13 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LD1-0010-200614 xenografted Balb / c nude mice with human PD-L1-positive cervical cancer. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; A 1.3 represents the toxin A 1.3 compound from Example 1, which is a free charged drug; DAR represents the charged drug:antibody ratio.

[0027] FIG. 14 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LD1-0015-362448 xenografted Balb / c nude mice with human PD-L1-positive esophageal squamous cell carcinoma. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; DAR represents the loaded drug:antibody ratio.

[0028] FIG. 15 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LD10017-200636 xenografted NU / NU mice with human PD-L1-positive gastric cancer. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; A 1.3 represents the toxin A 1.3 compound from Example 1, which is a free charged drug; DAR represents the charged drug:antibody ratio.

[0029] FIG. 16 is a graph showing the antitumor effect of the anti-PDL1 antibody-drug conjugate in PDX LD1 xenografted NU / NU mice. Petition 870250101969, dated 07 / 11 / 2025, page 17 / 312 10 / 89 2013-362125 with human PD-L1-positive colorectal cancer. Note: MAB20 represents an anti-PDL1 antibody whose amino acid sequence is shown in the Sequence Listing; MAB20-LP62 represents an antibody-drug conjugate formed by conjugating MAB20 to LP62; A 1.3 represents the toxin A 1.3 compound from Example 1, which is a free charged drug; DAR represents the charged drug:antibody ratio. Detailed description of the invention

[0030] This disclosure provides a novel anti-PDL1 antibody-drug conjugate. The anti-PDL1 antibody-drug conjugate exhibits good affinity for PDL1-positive cells, can be effectively internalized into PDL1-positive cells, and also displays good cell destruction effects, even in tumor cells insensitive to anti-PDL1. Furthermore, the anti-PDL1 antibody-drug conjugate has a good bystander effect and lower toxicity (especially immunotoxicity). In addition, the anti-PDL1 antibody-drug conjugate exhibits excellent tumor inhibitory activity in a variety of tumor models, even in tumor models with low PDL1 expression.

[0031] For the sake of clarity and not as a limitation, the detailed description of this disclosure is divided into the following subsections: 1. Definitions; 2. Antibody-drug conjugate; 3. Method of use; 4. Pharmaceutical formulation; and 5. Manufacturing article and kit. 1. Definitions

[0032] In this disclosure, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art, unless otherwise specified. Furthermore, the terms and laboratory operating steps relating to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are all of them. Petition 870250101969, dated 07 / 11 / 2025, page 18 / 312 11 / 89 conventional terms and steps that are widely used in the corresponding technique. In addition, for a better understanding of this disclosure, definitions and explanations of the related terms are provided below.

[0033] The terms PD-L1, PDL1, CD274, B7-H1 and programmed cell death ligand 1 are used interchangeably in this document and, unless otherwise specified, include any variants, isoforms and homologs of human PD-L1 that are commonly expressed by or in cells transfected with the PD-L1 gene.

[0034] The term antibody is used in its broadest sense and encompasses various antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antigen-binding fragments thereof, provided they exhibit the desired antigen-binding activity. The term antibody fraction refers to a full-length antibody or an antigen-binding fragment thereof.

[0035] The full-length antibody comprises two heavy chains and two light chains. The variable regions of the heavy and light chains are responsible for antigen binding. The variable domains of a heavy chain and a light chain may be referred to as Vh and Vl, respectively. The variable regions in both chains generally contain three highly variable loops called complementarity-determining regions (CDRs) (where light chain (LC) CDRs include LC CDR1, LC CDR2, and LC CDR3, and heavy chain (HC) CDRs include HC CDR1, HC CDR2, and HC CDR3). The limits of the CDRs of antibodies and antigen-binding fragments disclosed in this document can be defined or identified by the following conventions: Kabat, Chothia or Al-Lazikani (Al-Lazikani 1997, Chothia 1985, Chothia 1987, Chothia 1989, Kabat 1987 and Kabat 1991).The three CDRs of the heavy chain or of. Petition 870250101969, dated 07 / 11 / 2025, p. 19 / 312 12 / 89 light chains are interposed between flanking segments called framework regions (FRs), which are more highly conserved than CDRs and form a scaffold that supports the hypervariable loops. The constant regions of the heavy and light chains are not involved in antigen binding but exhibit various effector functions. Antibodies are classified into classes based on the amino acid sequence of the constant region of their heavy chain. The five main classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Several of the major antibody classes are divided into subclasses, such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgGA1 (α1 heavy chain), or IgGA2 (α2 heavy chain).

[0036] The term antigen-binding fragment, as used herein, refers to an antibody fragment including, for example, bispecific antibodies, Fab, Fab', F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide-stabilized bispecific antibody (ds bispecific antibody), a single-chain Fv (scFv), an scFv dimer (bivalent dibody), a multispecific antibody consisting of an antibody fraction comprising one or more CDRs, a camelized single-domain antibody, a nanobody, a domain antibody, a bivalent domain antibody or any other antibody fragment that binds to an antigen but does not contain a complete antibody structure. An antigen-binding fragment can bind to the same antigen to which the parental antibody binds, or a fragment of the parental antibody (e.g., a parental scFv) binds.In some embodiments, an antigen-binding fragment may comprise one or more CDRs of a particular human antibody, wherein one or more CDRs are grafted into structural regions of one or more different human antibodies.

[0037] As used in this document, the terms CDR or region Petition 870250101969, dated 07 / 11 / 2025, page 20 / 312 13 / 89 complementarity determinants are intended to designate non-contiguous antigen-binding sites found in the variable region of a heavy-chain and / or light-chain polypeptide. These specific regions were described in: Kabat et al., J. Biol. Chem., 252:6609 to 6616 (1977); Kabat et al., U.S. Department of Health and Human Services, Sequences of proteins of immunological interest (1991); Chothia et al., J. Mol. Biol. 196: 901 to 917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273: 927 to 948 (1997); MacCallum et al., J. Mol. Biol. 262: 732 to 745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832 to 3839 (2008); Lefranc MP et al., Dev. Comp. Immunol., 27: 55 to 77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657 to 670 (2001), in which the definition includes overlaps or subsets of amino acid residues after mutual alignment.However, the application of any of the definitions to refer to a CDR of an antibody or graft antibodies or variants thereof is intended to be within the scope of the term as defined and used in this document. The amino acid residues that comprise the CDRs, as defined by each of the references cited above, are presented below in Table 1 for comparison. Algorithms and interfaces for predicting CDRs are known in the art, including, for example, Abhinandan and Martin, Mol. Immunol., 45: 3832 to 3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38: D301 to D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43: D432 to D438 (2015). The content of the references cited in this paragraph is incorporated herein by reference in its entirety for use in this application and for possible inclusion in one or more claims herein. Table 1: Definitions of CDRs Kabat1 Chothia2 MacCallum3 IMGT4 AHo5 CDR1 da Vh 31-35 26-32 30-35 27-38 25-40 CDR2 da Vh 50-65 53-55 47-58 56-65 58-77 Petition 870250101969, dated 07 / 11 / 2025, page 21 / 312 14 / 89 CDR3 da Vh 95-102 96-101 93-101 105- 117 109- 137 CDR1 da Vl 24-34 26-32 30-36 27-38 25-40 CDR2 da Vl 50-56 50-52 46-55 56-65 58-77 CDR3 of Vl 89-97 91-96 89-96 105- 117 109- 137 1The waste numbering follows the nomenclature of Kabat et al., supra.2The waste numbering follows the nomenclature of Chothia et al., supra. 3The waste numbering follows the nomenclature of MacCallum et al., supra. 4. The numbering of the waste materials follows the nomenclature of Lefranc et al., supra. 5. The numbering of the waste materials follows the nomenclature of Honegger and Plückthun, supra.

[0038] The expressions numbering of variable domain residues as in Kabat or numbering of amino acid positions as in Kabat and variations thereof refer to a numbering system used for heavy chain variable domains or light chain variable domains from the antibody compilation by Kabat et al., supra. Using this numbering system, the actual linear amino acid sequence may contain fewer or more shortened or inserted amino acids corresponding to a FR or hypervariable region (HVR) of a variable domain. For example, a heavy chain variable domain may comprise a single amino acid insertion (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g., residues 82a, 82b, and 82c according to Kabat) after residue 82 of the heavy chain FR.The Kabat numbering of residues in a given antibody can be determined by aligning the antibody sequence with a standard Kabat-numbered sequence. Petition 870250101969, dated 07 / 11 / 2025, page 22 / 312 15 / 89 in regions of homology.

[0039] Unless otherwise specified herein, the amino acid residues encompassing the CDRs of a full-length antibody are defined according to Kabat nomenclature in Kabat et al., supra, and the numbering of residues in an immunoglobulin heavy chain, for example an Fc region, refers to the EU index numbering as described in Kabat et al., supra, except that the amino acid residues of the CDRs encompassing any consensus sequence are defined according to Kabat nomenclature, wherein modifications are based on experimental conditions. The EU index as described in Kabat refers to the residue numbering of a human IgG1 EU antibody.

[0040] Structural waste or FR is waste with a variable domain that is different from RDF waste as defined in this document.

[0041] A humanized form of a non-human (e.g., rodent) antibody is a chimeric antibody containing a minimal sequence derived from a non-human antibody. In most cases, a humanized antibody is a human immunoglobulin (receptor antibody) in which residues from the hypervariable region (HVR) of a receptor are replaced by residues from a hypervariable region (donor antibody) with the desired antigenic specificity, affinity, and capacity in a non-human species (e.g., a mouse, a rat, a rabbit, or a non-human primate). In some examples, residues from the structural region (FR) of a human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized antibody may comprise residues not found in the receptor antibody or the donor antibody. These modifications are made to further improve the antibody's performance.In general, a humanized antibody will comprise at least one, and typically substantially both, variable domains, in which all or substantially all hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all RFs are those of the human immunoglobulin sequence. Petition 870250101969, dated 07 / 11 / 2025, p. 23 / 312 16 / 89 A humanized antibody will also optionally comprise at least a portion of an immunoglobulin (Fc) constant region, typically at least a portion of a human immunoglobulin. For more details, see Jones et al., Nature, 321: 522-525, (1986); Riechmann et al., Nature, 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2: 593-596 (1992).

[0042] A human antibody is an antibody that has an amino acid sequence corresponding to that of an antibody produced in a human being and / or that has been produced using any technique as disclosed herein for the production of human antibodies. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage display libraries. Hoogenboom and Winter, J. Mol. Biol., 227: 381 (1991); and Marks et al., J. Mol. Biol., 222: 581 (1991). Also useful for the preparation of human monoclonal antibodies are the methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); and Boerner et al., J. Immunol., 147 (1): 86 to 95 (1991). See also van Dijk and van de Winkel, Curr. Opinion. Pharmacol., 5: 368 to 374 (2001).Human antibodies can be prepared by administering an antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been deactivated, for example immunized xenomice (see, for example, US patents nos. 6,075,181 and 6,150,584 for XENOMOUSE™ technology). See also, for example, Li et al., Proc. Natl. Acad. Sci. USA 103: 3557 to 3562 (2006) for human antibodies generated through human B-cell hybridoma technology.

[0043] Percentage (%) of amino acid sequence identity or homology, with respect to the polypeptide and antibody sequences identified in this document, is defined as the percentage of amino acid residues in a candidate sequence that are identical to the residues of Petition 870250101969, dated 07 / 11 / 2025, page 24 / 312 17 / 89 amino acids in the polypeptide being compared, after sequence alignment (considering any conservative substitutions as part of the sequence identity). Alignment, for the purpose of determining the percentage of amino acid sequence identity, can be achieved using various methods in the field, for example using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR) or MUSCLE. Experts in the technique can determine appropriate parameters for measuring alignment, including any algorithms necessary to achieve maximum alignment along the entire length of the sequences being compared. However, for the purposes of this document, the % amino acid sequence identity values ​​are generated using the MUSCLE sequence alignment computer program (Edgar, RC, Nucleic Acids Research, 32 (5): 1792 to 1797, 2004; and Edgar, RC)., BMC Bioinformatics 5 (1): 113, 2004).

[0044] Homologous refers to the similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When a position in the two sequences being compared is occupied by the same base or monomeric amino acid subunit, for example if a position in each of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percentage of homology between two sequences is a function of the number of corresponding or homologous positions shared by the two sequences divided by the number of positions being compared times 100. For example, if 6 out of 10 positions in two sequences are corresponding or homologous, the two sequences are 60% homologous. As an example, the DNA sequences ATTGCC and TATGGC share 50% homology. Generally, a comparison is made when two sequences are aligned to give maximum homology.

[0045] The term constant domain refers to a portion of an immunoglobulin molecule that has a more conserved amino acid sequence compared to another portion of the immunoglobulin, that is, a variable domain, which Petition 870250101969, dated 07 / 11 / 2025, p. 25 / 312 18 / 89 contains an antigen-binding site. A constant domain contains the Ch1, Ch2, and Ch3 domains (collectively referred to as Ch) of a heavy chain and a CHL (or Cl) domain of a light chain.

[0046] A light chain of an antibody (immunoglobulin) from any mammalian species can be classified into one of two clearly distinct types, called kappa (“κ”) and lambda (“λ”), respectively, based on the amino acid sequence of its constant domain.

[0047] The CH1 domain (also referred to as the C1 domain of the H1 domain) generally extends from about amino acid 118 to about amino acid 215 (EU numbering system).

[0048] A hinge region is generally defined as a region in IgG that corresponds to Glu216 to Pro230 of human IgG1 (Burton, Molec. Immunol., 22: 161 to 206 (1985)). The hinge regions of other IgG isotypes can be aligned with an IgG1 sequence by placing the first and last cysteine ​​residues that form SS linkages between heavy chains in the same positions.

[0049] The CH2 domain of a human IgG Fc region (also referred to as the C2 domain) typically extends from about amino acid 231 to about amino acid 340. The CH2 domain is unique in that it is not closely paired with another domain. Instead, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It has been speculated that the carbohydrate may provide a surrogate for domain-domain pairing and help stabilize the CH2 domain. Burton, Molec Immunol. 22:161-206 (1985).

[0050] The CH3 domain (also referred to as the C2 domain) comprises a region of residues in the Fc region near the C-terminus of the CH2 domain (i.e., from about amino acid residue 341 to the C-terminus of the antibody sequence (typically at residue 446 or 447 in IgG)).

[0051] The terms Fc region or crystallizable fragment region are used in this document to define a C-terminal region of a chain. Petition 870250101969, dated 07 / 11 / 2025, page 26 / 312 19 / 89 Immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the Fc region of human IgG heavy chain is typically defined as extending from an amino acid residue at the Cys226 position, or from Pro230, to the carboxyl terminus. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during antibody production or purification, or by recombinant engineering of the nucleic acid encoding an antibody heavy chain. Consequently, a composition of intact antibodies may include antibody populations from which all K447 residues have been removed, antibody populations from which no K447 residue has been removed, and antibody populations with a mixture of antibodies with and without the K447 residue.Suitable native Fc sequence regions for use in the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.

[0052] Fc receptor or FcR describes a receptor that binds to the Fc region of an antibody. A preferred FcR is a native human FcR. In addition, a preferred FcR is one that binds to an IgG antibody (γ receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic variants and forms that have undergone alternative splicing of these receptors, FcyRII receptors including FcyRIIA (activating receptor) and FcyRIIB (inhibiting receptor), which have similar amino acid sequences that differ mainly in their cytoplasmic domains. The FcyRIIA activating receptor contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The FcyRIIB inhibitory receptor contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (See M. Daeron, Annu. Rev. Immunol.)15:203 to 234 (1997). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9: 457 to 492 (1991); Capel et al., Immunomethods 4: 25 to 34 (1994); and. Petition 870250101969, dated 07 / 11 / 2025, p. 27 / 312 20 / 89 de Haas et al., J. Lab.Clin. Med. 126: 330 to 341 (1995). The term FcR in this document encompasses other FcRs, including those to be identified in the future.

[0053] As used in this document, the expressions specifically binds to, specifically recognizes, and is specific to refer to measurable and reproducible interactions, such as binding between a target and an antibody or antibody fraction, that are determinants of the target's presence in the presence of a heterogeneous population of molecules, including biological molecules. For example, an antibody or antibody fraction that specifically recognizes a target (which may be an epitope) is an antibody or antibody fraction that binds to this target with greater affinity, greater avidity, greater readiness, and / or greater duration than its binding to other targets. In some embodiments, the extent of antibody binding to an unrelated target is less than about 10% of the extent of antibody binding to the target, as measured, for example, by radioimmunoassay (RIA).In some embodiments, the dissociation constant of an antibody that specifically binds to a target is (Kd) < 10⁻⁵ M, < 10⁻⁶ M, < 10⁻⁷ M, < 10⁻⁸ M, < 10⁻⁹ M, < 10⁻¹⁰ M, < 10⁻¹¹ M, or < 10⁻¹² M. In some embodiments, an antibody specifically binds to an epitope of a protein that is conserved among proteins of various species. In some embodiments, specific binding may include, but does not require, exclusive binding. The binding specificity of an antibody or antigen-binding domain can be determined experimentally by a method known in the art. Such methods include, but are not limited to, Western blot assays, ELISA, RIA, ECL, IRMA, EIA, BIACORET, and peptide scans.

[0054] As used in this document, the term cytotoxic agent refers to a substance that inhibits or prevents cellular functions and / or causes cellular destruction. The term is intended to include: radioisotopes, for example the radioisotopes At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, C60 and Lu; chemotherapeutic agents; and toxins, such as small molecule toxins or toxins Petition 870250101969, dated 07 / 11 / 2025, p. 28 / 312 21 / 89 Enzymatic substances of bacterial, fungal, plant or animal origin, including synthetic analogues and derivatives thereof.

[0055] A linker, linking unit or linking element refers to a chemical module comprising a covalent bond or a chain of atoms that covalently links an antibody or targeting fraction to a drug module.

[0056] As used in this document, the terms antibody-drug conjugate, antibody conjugate, conjugate, immunoconjugate and ADC are used interchangeably and refer to a compound or derivative thereof linked to an antibody, for example an anti-PDL1 antibody, as defined by the following general formula: Ac-(LD)k, where Ac = antibody fraction (i.e., antibody or antigen-binding fragment), L = binding fraction, D = drug fraction and k = number of drug fractions conjugated per antibody fraction.

[0057] Among the currently commercially available antibody-drug conjugates, there are two main methods for conjugating an antibody to a linker: (1) Lysine is the most common binding site in antibodies, and an ε-amino group of it can react with an activated carboxyl group in the linker to form an amide bond. Currently, there are techniques that achieve site-directed conjugation by activating a carboxyl group in the linker with an activating group and then forming an amide bond with the ε-amino group of a specific lysine in the antibody. (2) The sulfhydryl (SH) groups of cysteines in an antibody all exist in the form of disulfide bonds (-SS-). Opening the disulfide bond in the antibody can provide a plurality of free sulfhydryl groups as conjugation sites.Conjugation to the antibody's sulfhydryl groups is achieved either by a Michael addition reaction between a free sulfhydryl group on the antibody and maleimide, or by double Michael addition reactions between a specific substrate and the free sulfhydryl group on the antibody to form a structurally unique bridging sulfur bond.

[0058] The three-letter and one-letter codes of amino acids as used Petition 870250101969, dated 07 / 11 / 2025, page 29 / 312 22 / 89 in the present document are described in J. Boil. Chem. 1968, 243, 3558.

[0059] As used in this document, the term halogen refers to fluorine, chlorine, bromine, or iodine.

[0060] As used in this document, the term alkyl refers to a saturated aliphatic hydrocarbon group, which is a linear or branched group containing 1 to 20 carbon atoms, preferably alkyl containing 1 to 12 carbon atoms, more preferably alkyl containing 1 to 10 carbon atoms, and even more preferably alkyl containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3dimethylpentyl, 2-ethylpentyl,3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl and various branched isomers thereof, etc. More preferably, the alkyl group is a short-chain alkyl group containing 1 to 6 carbon atoms, and non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl.etc. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point, the substituent preferably being one or more groups independently selected from among alkyl, alkenyl, alkynyl, alkoxy, etc. Petition 870250101969, dated 07 / 11 / 2025, p. 30 / 312 23 / 89 alkylthio, alkylamino, halogen, sulfhydryl, hydroxy, nitro, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo.

[0061] As used in this document, the term haloalkyl refers to alkyl substituted with one or more halogens, wherein the alkyl is as defined above.

[0062] As used in this document, the term cyano refers to -CN.

[0063] As used in this document, the expression sulfonic acid group refers to the -SO3H group.

[0064] As used in this document, the term carboxy refers to C(O)OH.

[0065] As used in this document, the term alkoxy refers to -O(alkyl) and -O-(cycloalkyl), wherein alkyl or cycloalkyl are as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy and cyclohexoxy. The alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio and heterocycloalkylthio.

[0066] The term alkenyl refers to an alkyl compound containing at least one carbon-carbon double bond in the molecule, wherein the alkyl is as defined above and the alkenyl has 2 to 10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms (i.e., C2-10 alkenyl). The alkenyl is preferably an alkenyl group with 2 to 6 carbon atoms (i.e., C2-6 alkenyl). The alkenyl may be substituted or unsubstituted. When substituted, the substituent is preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

[0067] The term alkynyl refers to an alkyl compound containing at least Petition 870250101969, dated 07 / 11 / 2025, p. 31 / 312 24 / 89 a carbon-carbon triple bond in the molecule, where the alkyl is as defined above and the alkenyl has 2 to 10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms (i.e., C2-10 alkynyl). The alkynyl is preferably an alkynyl group with 2 to 6 carbon atoms (i.e., C2-6 alkynyl). The alkynyl may be substituted or unsubstituted. When substituted, the substituent is preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

[0068] As used in this document, the term deuterated alkyl refers to alkyl substituted with one or more halogens, wherein the alkyl is as defined above.

[0069] This disclosure further includes various deuterated forms of formula (I). Each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom. Skilled in the art can synthesize deuterated forms of formula (I) by reference to relevant literature. Commercially available deuterated starting materials can be used in the preparation of deuterated forms of formula (I) or these can be synthesized using conventional techniques employing deuterated reagents, examples of which are not limiting: deuterated borane, a solution of a trideuterated borane in tetrahydrofuran, deuterated lithium aluminum hydride, deuterated iodoethane, deuterated iodomethane, etc.

[0070] As used in this document, the term DAR refers to the drug-to-antibody ratio, which represents the average number of cytotoxic drugs carried per antibody or may also represent the ratio between the amount of drug and the amount of antibody. The drug loading can range from 0 to 12, preferably from 1 to 10 cytotoxic drugs (D) conjugated per antibody (Ab). In one embodiment of this disclosure, the DAR is denoted as k, which can be an average value of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, for example, without limitation. The average number of drugs per ADC molecule after a conjugation reaction can be characterized by methods Petition 870250101969, dated 07 / 11 / 2025, p. 32 / 312 25 / 89 conventional methods, such as UV / visible spectroscopy, mass spectrometry, ELISA assay and HPLC.

[0071] In one embodiment of the present disclosure, the cytotoxic drug is conjugated to an exposed interchain cysteine ​​sulfhydryl (-SH) group of an antibody and / or a cysteine ​​sulfhydryl (-SH) group resulting from site-directed mutagenesis through a binding unit. Generally, the number of drug molecules that can be conjugated to the antibody in a conjugation reaction will be less than or equal to the theoretically maximum value.

[0072] The following non-limiting methods can be used to control the loading of a cytotoxic ligand-drug conjugate and include: (1) to control the molar ratio between a loaded drug-linker and a reducing agent and a monoclonal antibody, (2) to control the reaction time, temperature and pH value, and (3) to select different reaction reagents and their contents.

[0073] As used in this document, the terms solvated form or solvate mean that the drug-ligand conjugate of this disclosure forms a pharmaceutically acceptable solvate with one or more solvent molecules, examples of which, but not limited to, include water, ethanol, acetonitrile, isopropanol, DMSO, ethyl acetate, dimethylacetamide (DMAC), etc.

[0074] The term pharmaceutically acceptable salt, as used herein, refers to a pharmaceutically acceptable organic or inorganic salt of an antibody-drug conjugate. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tanninate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, sugar acid salt, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)). Pharmaceutically acceptable salts may involve the inclusion of another molecule, such as an acetate ion, an ion Petition 870250101969, dated 07 / 11 / 2025, page 33 / 312 26 / 89 succinate or other counterions. Counterions can be any organic or inorganic module that stabilizes the charge of the parent compound. Furthermore, pharmaceutically acceptable salts may have more than one charged atom in their structure. When a variety of charged atoms acts as a constituent of a pharmaceutically acceptable salt, there may be a variety of counterions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.

[0075] A pharmaceutically acceptable solvate refers to a combination of one or more solvent molecules and an ADC or a salt thereof. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0076] As used in this document, treatment or to treat is an approach to achieving beneficial or desired outcomes, including clinical outcomes. For the purposes of this application, beneficial or desired clinical outcomes include, but are not limited to, one or more of the following: relief of one or more symptoms resulting from the disease, reduction in the extent of the disease, stabilization of the disease (e.g., prevention or delay of disease worsening), prevention or delay of disease spread (e.g., metastasis), prevention or delay of disease recurrence, delay or retardation of disease progression, improvement in disease status, provision of a (partial or total) remission of the disease, reduction in the dose of one or more other drugs needed to treat the disease, delay of disease progression, increase or improvement in quality of life, increase in body weight gain and / or prolongation of survival.Treatment also includes a reduction in the pathological consequences of cancer (such as, for example, tumor volume). The method of the present application contemplates any one or more of these aspects of treatment.

[0077] In the context of cancer, the term treatment includes any or all of the following: inhibition of cancer cell growth, inhibition of cancer cell replication Petition 870250101969, dated 07 / 11 / 2025, page 34 / 312 27 / 89 cancer cells, reduction in overall tumor burden, and improvement in one or more disease-related symptoms.

[0078] The terms inhibition or inhibit refer to the reduction or cessation of any phenotypic characteristic, or to the reduction or cessation of the incidence, extent, or probability of that characteristic. Reducing or inhibiting refers to reducing, lowering, or preventing activity, function, and / or quantity compared to a reference. In certain embodiments, reducing or inhibiting refers to the ability to cause an overall decrease of 20% or more. In another embodiment, reducing or inhibiting refers to the ability to cause an overall reduction of 50% or more. In yet another embodiment, reducing or inhibiting refers to the ability to cause an overall reduction of 75%, 85%, 90%, 95% or more.

[0079] As used in this document, reference refers to any sample, standard, or level used for comparison purposes. The reference may be obtained from healthy and / or disease-free samples. In certain embodiments, the reference may be obtained from an untreated sample. In certain embodiments, the reference is obtained from a disease-free or untreated sample of an individual. In some examples, the reference is obtained from one or more healthy individuals who are not the individual or patient.

[0080] As used in this document, delaying the development of a disease refers to delaying, preventing, halting, slowing, stabilizing, inhibiting, and / or postponing the development of a disease, such as cancer. The delay may vary in terms of duration, depending on the history of the disease and / or the individual being treated. It would be obvious to those skilled in the art that a sufficient or significant delay may in fact include prevention, since the individual does not develop the disease. For example, it may delay advanced cancer (e.g., the development of metastases).

[0081] As used in this document, prevention includes providing protection against the occurrence or recurrence of a disease in an individual who may be predisposed to the disease but has not yet been treated. Petition 870250101969, dated 07 / 11 / 2025, page 35 / 312 28 / 89 diagnosed with the disease.

[0082] As used in this document, an inhibitory function or activity consists of a decrease in function or activity compared to the same condition, other than the condition or parameter of interest, or alternatively, compared to another condition. For example, antibodies that inhibit tumor growth reduce the rate of tumor growth compared to the rate of tumor growth in the absence of antibodies.

[0083] The terms subject, individual, and patient are used interchangeably in this document to refer to a mammal, including, but not limited to, a human being, a bovine, a horse, a feline, a canine, a rodent, or a primate. In some modalities, the individual is a human being.

[0084] An effective amount of an agent refers to the effective quantity, dosage, and time period required to achieve the desired therapeutic or prophylactic result. The specific dose may vary depending on one or more of the following: the particular agent selected, the dosing regimen to be followed, whether it will be administered in combination with other compounds, the time of administration, the tissue from which images will be obtained, and the physical delivery system that carries it.

[0085] The therapeutically effective amount of a substance / molecule, an agonist or an antagonist of the present application may vary depending on factors such as the disease state, age, sex and body weight of the individual, as well as the ability of the substance / molecule, agonist or antagonist to elicit the desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or harmful effects of the substance / molecule, agonist or antagonist are offset by the therapeutically beneficial effects. A therapeutically effective amount may be delivered in one or more administrations.

[0086] A prophylactically effective amount refers to an effective quantity, at the doses and for the time periods necessary, to achieve the desired result. Petition 870250101969, dated 07 / 11 / 2025, page 36 / 312 29 / 89 desired prophylactic dose. Typically, but not necessarily, since a prophylactic dose is used in a subject before or at an earlier stage of a disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0087] The terms pharmaceutical formulation and pharmaceutical composition refer to a preparation in a form that allows the biological activity of one or more active ingredients to be effective and does not include other components that are unacceptably toxic to the individual to whom the formulation is to be administered. Such formulations may be sterile.

[0088] A pharmaceutically acceptable vehicle refers to a non-toxic solid, semi-solid, or liquid carrier, a filler, diluent, encapsulating material, formulation aid, or conventional vehicle in the art, for use with a therapeutic agent, which together constitute a pharmaceutical composition for administration to an individual. The pharmaceutically acceptable vehicle is non-toxic to the recipient at the dose and concentration used and is compatible with the other ingredients of the formulation. A pharmaceutically acceptable vehicle is suitable for the formulation used.

[0089] It should be understood that, in the event that a chemical name is inconsistent with the chemical structure in the present application, the chemical structure shall prevail.

[0090] It should be understood that the modalities of the present application described in this document include modalities consisting of and / or consisting essentially of.

[0091] Reference to about a value or parameter in this document includes (and describes) variations that refer to that value or parameter per se. For example, the description referring to about X includes the description of X.

[0092] As used in this document, reference to not being a value or parameter generally means and describes a different value or parameter. For example, when a method is not used to treat type X cancer, it means that the method is used to treat cancers other than type X. Petition 870250101969, dated 07 / 11 / 2025, page 37 / 312 30 / 89

[0093] As used in this document, the expression about XY has the same meaning as about X to about Y.

[0094] As used in this document, the modification of the quantity of an ingredient or reagent in this disclosure with the expression "about" is a variation in quantity of a numerical value that may occur, for example, in typical measurements and liquid treatment procedures used to prepare concentrates or solutions actually used; in occasional errors in these procedures; in differences in the manufacture, sources, or purity of ingredients used to prepare the composition or carry out the method; etc. The expression "about" also includes quantities that differ due to different equilibrium conditions with respect to a composition resulting from a particular starting mixture. Regardless of whether or not they are modified by the expression "about," the quantity equivalents are included in the claims.In one modality, the expression "approximately" means being within 10% of the reported numerical value, preferably within 5% of the reported numerical value.

[0095] Skilled in the art, it shall be understood that when a numerical value is mentioned in the claims, whether or not it has the prefix about, the actual value of the numerical value may vary by 10% (± 10%) relative to the stated value, preferably by 5% (± 5%).

[0096] As used in this document and the accompanying claims, the singular forms a, an, or and the include plural referents, unless the context clearly indicates otherwise. 2. Antibody-drug conjugate

[0097] An anti-PD-L1 antibody can be conjugated to a cytotoxic or cytostatic fraction (including a pharmaceutically compatible salt thereof) to form an antibody-drug conjugate (ADC). Fractions particularly suitable for antibody conjugation are cytotoxic agents (e.g., chemotherapeutic agents), prodrug-converting enzymes, radioisotopes, or compounds or toxins (these fractions are collectively referred to as agents). Petition 870250101969, dated 07 / 11 / 2025, pages 38 / 312 31 / 89 therapeutic). For example, the anti-PD-LI antibody can be conjugated to a cytotoxic agent, such as a chemotherapeutic agent or a toxin (for example, a cytostatic agent or a cell-killing agent, such as, for example, abrin, ricin A, Pseudomonas exotoxin or diphtheria toxin).

[0098] The anti-PD-L1 antibody can be conjugated to a prodrug-converting enzyme. The prodrug-converting enzyme can be recombinantly fused with, or chemically conjugated to, the antibody using a known method. Exemplary prodrug-converting enzymes are carboxypeptidase G2, β-glucuronidase, penicillin-V-amidase, penicillin-G-amidase, β-lactamase, β-glucosidase, nitroreductase, and carboxypeptidase A.

[0099] Techniques for combining therapeutic agents with proteins, particularly antibodies, are well known. (See, for example, Arnon et al., Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy, in Monoclonal Antibodies And Cancer Therapy (Reisfeld et al. eds., Alan R. Liss, Inc., 1985); Hellstrom et al., Antibodies For Drug Delivery, in Controlled Drug Delivery (Robinson et al. eds., Marcel Dekker, Inc., 2nd edition, 1987); Thorpe, Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review, in Monoclonal Antibodies'84: Biological And Clinical Applications (Pinchera et al. eds., 1985); 1985); and Thorpe et al., 1982, Immunol. Rev. 62:119 to 58. See also, for example, PCT publication no. WO 89 / 12624.)

[0100] The therapeutic agent may be conjugated in a manner that reduces its activity unless it is cleaved from the antibody (e.g., by hydrolysis, antibody degradation, or a cleavage agent). Such a therapeutic agent is linked to the antibody using a cleavable linker that is sensitive to cleavage in the intracellular environment or in the tumor microenvironment of cancer cells expressing PD-L1, so that it is cleaved from the antibody. Petition 870250101969, dated 07 / 11 / 2025, pages 39 / 312 32 / 89 antibody when the conjugate is in that environment (e.g., in endosomes or, for example, due to pH sensitivity or protease sensitivity in lysosomal environments, in caveolar environments, or in the tumor microenvironment).

[0101] Typically, the ADC comprises a binding region between the therapeutic agent and the anti-PD-L1 antibody. As described above, the linker is typically cleavable under intracellular conditions or in the tumor microenvironment, such that linker cleavage occurs in the intracellular environment (e.g., in lysosomes or endosomes or caveolae) or in the tumor microenvironment, leading to the release of the therapeutic agent from the antibody. The linker may be, for example, a peptidyl linker that is cleaved by intracellular peptidases or proteases, including lysosomal or endosomal proteases. Typically, the peptidyl linker has a length of at least two amino acids or at least three amino acids. Cleavage agents may include cathepsins B and D, plasmin, etc. (See, for example, Dubowchik and Walker, 1999, Pharm. Therapeutics 83: 67-123).The most typical peptidyl linkers are peptidyl linkers cleaved by enzymes present in cells expressing PD-L1 or in the tumor microenvironment. For example, peptidyl linkers cleaved by the thiol-dependent protease cathepsin B, which can be highly expressed in cancerous tissues, can be used (e.g., a linker containing a Phe-Leu or Gly-Phe-Leu-Gly peptide). Other such linkers are described, for example, in U.S. Patent No. 6,214,345. In a specific embodiment, a peptidyl linker cleaved by an intracellular protease includes a Val-Cit linker or a Phe-Lys dipeptide (see, for example, U.S. Patent 6,214,345, which describes the synthesis of doxorubicin using the Val-Cit linker). One advantage of using intracellular proteolysis to release the therapeutic agent is that the agent typically decays during conjugation, and the serum stability of the conjugate is generally high.

[0102] Cleavable linkers can be pH-sensitive, that is, sensitive to hydrolysis at certain pH values. Typically, pH-sensitive linkers are hydrolyzable. Petition 870250101969, dated 07 / 11 / 2025, page 40 / 312 33 / 89 under acidic conditions. For example, acid-labile ligands that are hydrolyzable in lysosomes may be used (e.g., hydrazones, hemicarbazones, thiosemicarbazones, cis-aconitic amide, orthoesters, acetals, and ketals). (See, for example, U.S. Patents Nos. 5,122,368, 5,824,805, and 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics, 83:67–123; and Neville et al., 1989, Biol. Chem. 264:14653–14661). These linkers are relatively stable under neutral pH conditions, such as those of blood, but are not stable below pH 5.5 or 5.0 (the approximate pH of lysosomes). In certain embodiments, a hydrolyzable linker is a thioether linker (such as a thioether linked to a therapeutic agent via an acyl-hydrazone linkage) (see, for example, US Patent No. 5,622,929).

[0103] Other linkers, such as disulfide linkers, are cleavable under reducing conditions. Disulfide linkers include those that can be formed with SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT (N-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene), SPDB and SMPT. See, for example, Thorpe et al., 1987, Cancer Res. 47: 5924 to 5931; Wawrzynczak et al., Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer (CW Vogel eds., Oxford U. Press, 1987. See also US Patent No. 4,880,935.)

[0104] The linker may also be a malonate linker (Johnson et al., 1995, Anticancer Res. 15: 1387 to 1393), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3 (10):1299 to 1304) or 3'-N-amide analogs (Lau et al., 1995, Bioorg-Med-Chem. The linker may also be a malonate linker (Johnson et al., 1995, Anticancer Res. 15: 1387 to 1393), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3 (10):1299 to 1304) or 3'-N-amide analogs (Lau et al., 1995, Bioorg-Med-Chem.

[0105] The linker may also be a non-cleavable linker, such as a maleimido-alkylene or maleimido-aryl linker directly attached to an agent. Petition 870250101969, dated 07 / 11 / 2025, p. 41 / 312 34 / 89 therapeutic (e.g., a drug). The active drug-binding agent is released by the degradation of the antibody.

[0106] Typically, the linker is substantially insensitive to the circulatory system environment, meaning that when ADC is present in plasma, no more than about 20%, typically no more than about 15%, more typically no more than about 10%, even more typically no more than about 5%, no more than about 3%, or no more than about 1% of the linker in an ADC sample is cleaved.

[0107] It can be determined whether the ligand is substantially insensitive to the circulatory system environment, for example, by: incubating (a) the ADC (ADC sample) and (b) an equimolar amount of an unconjugated antibody or therapeutic agent (control sample), independently, with plasma for a predetermined period of time (e.g., 2, 4, 8, 16 or 24 hours), and then comparing the amount of unconjugated antibody or therapeutic agent present in the ADC sample, as measured, for example, by high-performance liquid chromatography, with the amount present in the control sample.

[0108] The anti-PDL1 antibody can be conjugated to the linker through a heteroatom in the antibody. Such heteroatoms may be naturally present in the antibody or may be introduced into the antibody. In some aspects, the anti-PDL1 antibody will be conjugated to the linker through the nitrogen atom of the lysine residue. In other aspects, the anti-PDL1 antibody will be conjugated to the linker through the sulfur atom of the cysteine ​​residue. The cysteine ​​residue may be a naturally occurring residue or one that is introduced into the antibody. Methods for conjugating linkers and drug-linkers to antibodies through lysine and cysteine ​​residues are known in the art.

[0109] Exemplary antibody-drug conjugates also include camptothecin-based antibody-drug conjugates (i.e., the pharmacological component is the drug camptothecin). Camptothecin is an inhibitor of Petition 870250101969, dated 07 / 11 / 2025, page 42 / 312 35 / 89 topoisomerase, which has proven to have anticancer activity. Typically, the camptothecin-based antibody-drug conjugate comprises a linker between the camptothecin drug and the anti-PDL1 antibody. The linker may be, for example, a cleavable linker (e.g., a peptidyl linker or a carbohydrate linker) or a non-cleavable linker (e.g., a linker released by antibody degradation). The synthesis and structure of exemplary camptothecin drug linkers are described in PCT / US19 / 025968, which is incorporated herein by reference in its entirety for all purposes.

[0110] Other exemplary antibody-drug conjugates include maytansinoid antibody-drug conjugates (i.e., the pharmacological component is a maytansinoid drug) and benzodiazepine antibody-drug conjugates (i.e., the pharmacological component is a benzodiazepine (e.g., a pyrrolo[1,4]benzodiazepine dimer (PBD dimer), an indolobenzodiazepine dimer, and an oxazolidinobenzodiazepine dimer).

[0111] Useful classes of cytotoxic agents conjugated to anti-PDL1 antibodies include, for example, anti-tubulin agents, DNA minor groove agglutinators, DNA replication inhibitors, chemotherapeutic sensitizers, etc. Other exemplary classes of cytotoxic agents include anthracyclines, auristatins, camptothecins, duocarmycin, etoposide, maytansinoids, and vinca alkaloids. Some examples of cytotoxic agents include camptothecins (e.g., irinotecan and DXD), auristatins (e.g., auristatin T, auristatin E, AFP, monomethylauristatin F (MMAF), lipophilic monomethylauristatin F, monomethylauristatin E (MMAE)), DNA minor groove binders (e.g., enediins and lexitropsins), duocarmycin, taxanes (e.g., taxol and docetaxel), vinca alkaloids, nicotinamide phosphoribosyltransferase inhibitors (NAMPTi), tubulisin M, doxorubicin, morpholinodoxorubicin, and cyclomorpholinodoxorubicin.

[0112] The cytotoxic agent may be a chemotherapeutic agent such as, for example, doxorubicin, taxol, melphalan, vinca alkaloids, methotrexate, Petition 870250101969, dated 07 / 11 / 2025, page 43 / 312 36 / 89 mitomycin C or etoposide. The agent may also be an analogue of CC-1065, calicheamicin, maytansine, a dolastatin analogue 10, rhizoxine, or palloxine.

[0113] The cytotoxic agent may also be auristatin. Auristatin may be a derivative of auristatin E, such as an ester formed between auristatin E and a keto acid. For example, auristatin E may react with p-acetylbenzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively. Other typical auristatins include auristatin T, AFP, MMAF, and MMAE. The synthesis and structure of several auristatins are described, for example, in US 2005-0238649 and US 2006-0074008.

[0114] This disclosure discloses an antibody-drug conjugate, a method for its preparation and its use, in particular a conjugate of an anti-PD-L1 antibody and a novel topoisomerase (TOP) I inhibitor that is more sensitive to tumors, a pharmaceutical composition thereof, a method for its preparation and its use. Through antitumor experiments, the resulting antibody-drug conjugate has been found to have improved activity, such as potent antitumor activity. It significantly improves the survival of tumor-bearing animals, has significantly reduced toxicity, less burden on the bodies of experimental animals and a significantly reduced minimum effective dose of the small molecule drug when used alone, expands its therapeutic window, is promising for use in the development of drugs to treat a variety of diseases such as tumors and shows good prospects for application and value.

[0115] The anti-PDL1 antibody-drug conjugate of the present disclosure is a novel antibody-drug conjugate (ADC) targeting PDL1 consisting essentially of three fractions, namely a monoclonal antibody targeting PDL1, a small molecule drug (payload) and a tumor microenvironment-sensitive linker (linker), wherein the loaded drug is a novel topoisomerase (TOP) I inhibitor that is more sensitive to tumors. After the anti-PDL1 antibody-drug conjugate of the present disclosure enters the Petition 870250101969, dated 07 / 11 / 2025, p. 44 / 312 37 / 89 body, one part of the anti-PDLI-drug conjugate can release the loaded drug into the tumor microenvironment after specific binding of the antibody fraction thereof to PDL1 highly expressed in tumor cells while the other part enters cancer cells via PDL1-mediated drug internalization. In a special environment in tumors, the peptide linker of the anti-PDL1-drug antibody conjugate of the present disclosure is cleaved to effectively release the payload, and the loaded small molecule drug exerts a cytotoxic effect, thus potentially killing cancer cells in a targeted manner. Due to relatively high lipophilicity, some payloads may exert a bystander effect, allowing their action after entering cells surrounding cancer cells, while PDL1-targeted ADCs have the potential to block PD-1 / PDL1 immune checkpoints.These anti-cancer mechanisms of action are also effective against low antigen expression and negative tumor cells. The anti-PDL1 antibody-drug conjugate of this disclosure is expected to be an ideal therapeutic drug for the following patients: patients who have had an unsatisfactory response to PD-1 / PDL1 inhibitor therapy or progression after PD-1 / PDL1 inhibitor therapy.

[0116] The anti-PDL1 antibody-drug conjugate of this disclosure has the following characteristics: (1) A new generation of linker type that is relatively sensitive to the tumor microenvironment is used to ensure the stability of ADC drugs in the bloodstream and to allow effective release of the loaded small molecule drug into tumor cells or when in the tumor microenvironment. (2) Drugs loaded (payloads) with the new generation of mechanism of action are used to effectively kill cancer cells with different levels of PDL1 expression. (3) A new generation of antibody conjugation technology is used to ensure consistency and accuracy of the conjugation site of Petition 870250101969, dated 07 / 11 / 2025, page 45 / 312 38 / 89 antibody, so that the half-life and immunogenicity of the conjugate are similar to those of the antibody, while the PD-1 / PDL1 immune checkpoint blocking function of the antibody fraction is maintained.

[0117] In some respects, the present disclosure provides an antibody-drug conjugate, a prodrug, a pharmaceutically acceptable salt or a solvate thereof, or a solvate of the pharmaceutically acceptable salt, wherein the antibody-drug conjugate has a structure represented by formula (I): TP-[L1-L2-L3-D]k (I) where TP is a targeting fraction that selectively binds to or recognizes PDL1; L1 is an extension unit that connects TP and L2, wherein TP is connected to L1 via an active group (e.g., sulfhydryl or amino group), preferably wherein L1 is conjugated to an interchain cysteine ​​sulfhydryl (-SH) group exposed in TP and / or a cysteine ​​sulfhydryl (-SH) group resulting from site-directed mutagenesis; L2 is an optional amino acid residue or a short peptide consisting of 2 to 10 amino acid residues; L3 is a spacer element; D is a biologically active molecule; ek represents any numerical value between 0.1 and 10.0.

[0118] With reference to the antibody-drug conjugate, the subscript k represents the drug loading and, depending on the context, may represent the molecular number of drug-linker molecules bound to the individual antibody molecule; therefore, it is an integer value; alternatively, k may represent the average drug loading and, consequently, may be an integer or non-integer value. The average drug loading represents the average number of drug-linker molecules per antibody in a population. Usually, but not always, when we refer to antibodies, we use the term antibodies. Petition 870250101969, dated 07 / 11 / 2025, p. 46 / 312 39 / 89 monoclonal antibodies, when referring to a population of antibody molecules. In a composition comprising a population of antibody-drug conjugate molecules, the average drug loading is an important mass attribute, as it determines the amount of drug that can be delivered to the target cell. The percentage of unconjugated antibody molecules in the composition is included in the average drug loading value.

[0119] In a preferred aspect of the present disclosure, when referring to a composition comprising a population of antibody-drug conjugate compounds, the average drug loading is from 1 to about 16, preferably from about 2 to about 14, more preferably from about 2 to about 10.

[0120] For ADCs with MMAE and camptothecin, such as those exemplified in this document, a preferred average drug loading is about 2, 4, or 8, and a particularly preferred average drug loading is about 8. In one embodiment, a preferred average drug loading for an ADC with MMAE is 2 or 4. In another embodiment, a preferred average drug loading for an ADC with camptothecin is 4 or 8. In an exemplary embodiment, the linker drug is conjugated to a cysteine ​​residue in a reduced interchain disulfide. In some respects, the actual drug loading per individual antibody molecule in a population of antibody-drug conjugate compounds is 1 to 10 (or 6 to 10 or 6 to 8), wherein the predominant drug loading is 8.

[0121] In some embodiments of formula (I), the TP is an antigen-binding antibody or fragment thereof.

[0122] In some embodiments of formula (I), the antigen-binding fragment is selected from a full-length immunoglobulin, a single-chain Fv fragment (scFv), a Fab fragment, a Fab' fragment, an F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), a (dsFv)2, an Fv-Fc fusion, an scFv-Fc fusion, an scFv-Fv fusion, a diabody, a tribody, a tetrabody, or any combination thereof.

[0123] In some embodiments of formula (I), TP is a humanized antibody Petition 870250101969, dated 07 / 11 / 2025, page 47 / 312 40 / 89 or a fragment of the same that binds to the antigen.

[0124] In some embodiments of formula (I), the TP comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the heavy chain variable region (HV) comprises the heavy chain complementarity determining region 1 (HCDR1), HCDR2 and HCDR3 contained in SEQ ID NO: 7, and the light chain variable region (LV) comprises the light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3 contained in SEQ ID NO: 8.

[0125] In some embodiments of formula (I), the amino acid sequence of HCDR1 is SEQ ID NO: 1, the amino acid sequence of HCDR2 is SEQ ID NO: 2 and the amino acid sequence of HCDR3 is SEQ ID NO: 3; and the amino acid sequence of LCDR1 is SEQ ID NO: 4, the amino acid sequence of LCDR2 is SEQ ID NO: 5 and the amino acid sequence of LCDR3 is SEQ ID NO: 6.

[0126] In some embodiments of formula (I), TP comprises a human IgG Fc sequence.

[0127] In some embodiments of formula (I), IgG is selected from IgG1, IgG2, IgG3 and IgG4.

[0128] In some embodiments of formula (I), the TP comprises a variable heavy chain (VH) region and the amino acid sequence of the variable heavy chain (VH) region has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO: 7.

[0129] In some embodiments of formula (I), the TP comprises a variable light chain (VL) region and the amino acid sequence of the variable light chain (VL) region has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO: 8.

[0130] In some embodiments of formula (I), the TP comprises a heavy chain (HC) and the amino acid sequence of the heavy chain (HC) has at least Petition 870250101969, dated 07 / 11 / 2025, p. 48 / 312 41 / 89 less than 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% match with SEQ ID NO: 9.

[0131] In some embodiments of formula (I), the TP comprises a light chain (LC) and the amino acid sequence of the heavy chain (LC) has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO: 10.

[0132] In some embodiments of formula (I), TP is a multispecific antibody.

[0133] In some embodiments of formula (I), TP is an afucosylated antibody.

[0134] In some embodiments of formula (I), the Fc region comprises a C-terminal lysine.

[0135] In some embodiments of formula (I), the Fc region comprises a deletion of the C-terminal lysine.

[0136] In some forms of formula (I), L1 is selected from where L1 is connected to TP at position a through an S atom and to L2 at position b, m is any integer between 1 and 10, n is any integer between 1 and 10, and X and Y are each independently C, O, S, or N.

[0137] In some forms of formula (I), L1 is where m is selected from 1, 2, 3, 4 or 5, Petition 870250101969, dated 07 / 11 / 2025, p. 49 / 312 42 / 89 where L1 is connected to TP at position a via a sulfur atom and to L2 at position b.

[0138] In some forms of formula (I), L1 is where L1 is connected to TP at position a via a sulfur atom and to L2 at position b.

[0139] In some embodiments, L1 is connected to a TP cysteine ​​(more specifically, to the cysteine ​​sulfhydryl group) at the α position.

[0140] In some forms of formula (I), L2 is selected from where L2 is connected to L1 at position ce and L3 at position d.

[0141] In some embodiments of formula (I), L2 is Petition 870250101969, dated 07 / 11 / 2025, page 50 / 312 43 / 89 where L2 is connected to L1 in position ce and L3 in position d.

[0142] In some embodiments of formula (I), L3 is a single link or a group selected from: where L3 is connected to L2 at position e and D at position f, Z is selected from hydrogen, halogen, C1-C20 alkyl, C1-C20 haloalkyl, cyano, sulfo, carboxyl, C1-C20 alkoxy, unsaturated C2-C10 alkyl, a natural amino acid, a non-natural amino acid, and a short peptide consisting of the above amino acids.

[0143] In some embodiments of formula (I), Z is selected from Petition 870250101969, dated 07 / 11 / 2025, page 51 / 312 44 / 89 where Z is connected to the remainder of L3 at position g, z1 to z9 are each independently an integer between 0 and 10, and T is NH2 or OH.

[0144] In some embodiments of formula (I), D is a cytotoxic agent.

[0145] In some embodiments of formula (I), D is selected from where D is connected to L3 at position h.

[0146] In some embodiments of formula (I), the antibody-drug conjugate is selected from: Petition 870250101969, dated 07 / 11 / 2025, p. 52 / 312 45 / 89 Petition 870250101969, dated 07 / 11 / 2025, p. 53 / 312 46 / 89 Petition 870250101969, dated 07 / 11 / 2025, p. 54 / 312 47 / 89

[0147] Ac represents the antibody or antigen-binding fragment thereof as defined in the preceding embodiments.

[0148] In some embodiments of formula (I), k is 0,1,0,2, 0,3, 0,4, 0,5, 0,6, 0,7, 0,8, 0,9, 1,0, 1,1, 1,2, 1,3, 1,4, 1,5, 1,6, 1,7, 1,8, 1,9,2,0,2,1,2,2,2,3,2,4,2,5,2,6, 2,7, 2,8, 2,9, 3,0, 3,1,3,2, 3,3, 3,4, 3,5, 3,6, 3,7, 3,8, 3,9, 4,0, 4,1,4,2, 4,3, 4,4, 4,5, 4,6, 4,7, 4,8, 4,9, 5,0, 5,1,5,2, 5,3, 5,4, 5,5, 5,6, 5,7, 5,8, 5,9, 6,0, 6,1,6,2, 6,3, 6,4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, or it is in a range between any two of them. In other modalities, k is 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0 or lies within a range between any two of them. In other modalities, k is 4.0, 6.0 or 8.0. 3. Method of use

[0149] The anti-PDL1 antibody-drug conjugate of this disclosure can be used to treat cancer. Some of these cancers have levels Petition 870250101969, dated 07 / 11 / 2025, page 55 / 312 48 / 89 detectable PDL1 molecules measured at the protein level (e.g., by immunoassay using one of the antibodies exemplified) or mRNA level. Some of these cancers exhibit elevated PDL1 levels relative to the same type of non-cancerous tissue, preferably from the same patient. An exemplary PDL1 level in treatable cancer cells is 5,000 to 500,000 PDL1 molecules per cell; however, those with higher or lower levels may be treatable. Optionally, the PDL1 level in the cancer is measured before treatment.

[0150] Examples of cancers related to PDL1 expression and suitable for treatment include melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, breast cancer (e.g., triple-negative breast cancer (TNBC)), pancreatic cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), esophageal cancer, bladder cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, prostate cancer, pancreatic cancer, and glioma. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat melanoma. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat NSCLC. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat SCLC.In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat head and neck cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat breast cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat TNBC. Triple-negative breast cancer is a specific expression of cancer that lacks detectable estrogen and progestin receptors and lacks HER2 / neu overexpression. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat pancreatic cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat ovarian cancer. Petition 870250101969, dated 07 / 11 / 2025, p. 56 / 312 49 / 89 In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat urothelial cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat hepatic cell carcinoma (HCC). In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat esophageal cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat gastric cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat cervical cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat kidney cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat prostate cancer.In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat pancreatic cancer. In some embodiments, the antibody or antibody-drug conjugate of this disclosure is used to treat glioma. Treatment may be applied to patients with these types of primary or metastatic tumors. Treatment may also be applied to patients refractory to conventional treatment or who have relapsed after responding to such treatment.

[0151] The antibody-drug conjugate of this disclosure is administered in an effective regimen that represents a dose, route of administration, and frequency of administration that can delay the onset, reduce the severity, inhibit further exacerbation, and / or improve at least one sign or symptom of cancer. If the patient has a history of cancer, the regimen may be referred to as a therapeutically effective regimen. If the patient has an increased risk of developing cancer compared to the general population but has no symptoms, the regimen may be referred to as a prophylactically effective regimen. In some cases, therapeutic or prophylactic efficacy may be observed in individual patients relative to historical controls or past experience in the same patient. In other cases, therapeutic or prophylactic efficacy in pre-trial trials Petition 870250101969, dated 07 / 11 / 2025, page 57 / 312 50 / 89 clinical or clinical outcomes can be demonstrated in relation to a control population of untreated patients.

[0152] An exemplary dose of the antibody-drug conjugate may be 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg to 20 mg / kg), for example 1 mg / kg to 7.5 mg / kg or 2 mg / kg to 7.5 mg / kg or 3 mg / kg to 7.5 mg / kg of the subject's body weight, or 0.1 to 20 mg / kg of body weight or 0.5 to 5 mg / kg of body weight (e.g., 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg or 10 mg / kg), or a fixed dose of 10 to 1500 mg or 200 to 1500 mg. In some methods, the patient is given a dose of at least 1 mg / kg, at least 1.5 mg / kg, at least 2 mg / kg, at least 3 mg / kg, at least 8 mg / kg, or at least 10 mg / kg, once a week, once every three weeks, or less frequently. The dose depends on factors such as the frequency of administration, the patient's condition and response, if any, to previous treatment, whether the treatment is prophylactic or therapeutic, and whether the disorder is acute or chronic.

[0153] Administration may be parenteral, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, local, intranasal, or intramuscular. Administration may also be localized directly into the tumor. It is preferably administered into the systemic circulation by intravenous or subcutaneous administration. Intravenous administration may be performed, for example, by infusion over a period of time (e.g., 30 to 90 min) or by a single bolus injection.

[0154] The frequency of administration depends on factors such as the half-life of the circulating conjugate, the patient's condition, and the route of administration. The frequency may be once daily, once weekly, once monthly, once quarterly, or at irregular intervals in response to changes in the patient's condition or the progression of the cancer being treated. During a continuous course of treatment, an exemplary frequency of intravenous administration is between twice weekly and once quarterly, but administration may also be more frequent or Petition 870250101969, dated 07 / 11 / 2025, page 58 / 312 51 / 89 less. During a continuous course of treatment, other exemplary frequencies of intravenous administration are between once a week or three times every four weeks, but administration may also be more or less frequent. For subcutaneous administration, exemplary dosing frequencies are once a day to once a month, but administration may also be more or less frequent.

[0155] The number of doses administered depends on the nature of the cancer (e.g., presentation of acute or chronic symptoms) and the response of the disorder to treatment. Between 1 and 10 doses are usually sufficient for acute disorders or acutely exacerbated chronic disorders. Sometimes, single bolus doses (optionally in separate forms) are sufficient for acute disorders or acutely exacerbated chronic disorders. Recurrence or acute exacerbation of acute disorders may be treated repeatedly. For chronic diseases, antibodies may be administered at regular intervals, for example once a week, once every two weeks, once a month, once a quarter, or once every six months for at least 1, 5, or 10 years, or for the patient's life expectancy.

[0156] Pharmaceutical compositions for parenteral administration are preferably sterile and substantially isotonic, being manufactured under GMP conditions. The pharmaceutical compositions may be supplied in a unit dosage form (i.e., a dose for a single administration). The pharmaceutical compositions may be formulated using one or more physiologically acceptable vehicles, diluents, excipients, or auxiliaries. The formulation depends on the chosen route of administration. For injection, the antibody may be formulated in an aqueous solution, preferably in a physiologically compatible buffer such as Hank's solution, Ringer's solution, or normal saline, or in acetate buffer to reduce discomfort at the injection site. The solution may contain formulation agents such as suspending agents, stabilizers, and / or dispersing agents. Alternatively, prior to use, the antibody may be in a lyophilized form for constitution in a Petition 870250101969, dated 07 / 11 / 2025, p. 59 / 312 52 / 89 suitable vehicle (e.g., sterile pyrogen-free water). The antibody concentration in a liquid formulation can be, for example, 1 to 100 mg / mL, such as 10 mg / mL.

[0157] Treatment with the antibody-drug conjugate of this disclosure may be combined with chemotherapy, radiation, stem cell therapy, surgery, or other therapies that are effective for the disorder being treated.Useful classes of other agents that can be administered with PDL1-drug targeted antibody conjugates as described herein include, for example, antibodies targeting other receptors expressed on cancer cells, anti-tubulin agents (e.g., auristatins), minor groove DNA agglutinators, DNA replication inhibitors, alkylating agents (e.g., platinum complexes such as cisplatin, mono(platinum), bis(platinum) and trinuclear platinum complexes, and carboplatin), anthracyclines, antibiotics, antifolates, antimetabolites, chemotherapeutic sensitizers, duocarmycin, etoposide, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinols, pre-formed compounds, purine antimetabolites, puromycin, radiosensitizers, steroids, taxanes, topoisomerase inhibitors, vinca alkaloids, etc.

[0158] Treatment with an antibody-drug conjugate, optionally in combination with any of the other agents or regimens described above, can increase median progression-free survival or overall survival time of a patient with a tumor (e.g., melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, breast cancer (e.g., triple-negative breast cancer (TNBC)), pancreatic cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), esophageal cancer, gastric cancer, colorectal cancer, and cervical cancer), especially in the case of recurrent or refractory tumors, by at least 30% or 40%, but preferably by 50%, 60% to 70%, or even 100% or more, compared with the same treatment (e.g., chemotherapy) without the antibody-drug conjugate. Petition 870250101969, dated 07 / 11 / 2025, page 60 / 312 53 / 89 antibody-drug conjugate. Additionally or alternatively, treatment comprising the antibody-drug conjugate (e.g., standard chemotherapy) may increase the complete response rate, the partial response rate, or the objective response rate (complete + partial) of a patient with a tumor by at least 30% or 40%, but preferably by 50%, 60% to 70%, or even 100%, compared with the same treatment (e.g., chemotherapy) without the antibody-drug conjugate. 4. Pharmaceutical formulation

[0159] Although the antibody-drug conjugate described in this document can be used alone (e.g., by administration), it is generally present, preferably, in a composition or formulation.

[0160] In one aspect, the composition is a pharmaceutical composition (e.g., formulation, preparation or agent) comprising the antibody-drug conjugate described herein and a pharmaceutically acceptable vehicle, diluent or excipient.

[0161] In one aspect, the composition is a pharmaceutical composition comprising at least one of the antibody-drug conjugates described herein and one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including but not limited to vehicles, diluents, excipients, adjuvants, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavorings and pharmaceutically acceptable sweeteners.

[0162] In one aspect, the composition also includes other active agents, such as other therapeutic or prophylactic agents.

[0163] Suitable vehicles, diluents, excipients, etc. can be found in standard pharmaceutical literature. See, for example, Handbook of Pharmaceutical Additives, 2nd edition (editions M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA), Remington's Pharmaceutical Sciences, 20th edition, Lippincott, Williams & Wilkins, 2000; and Petition 870250101969, dated 07 / 11 / 2025, page 61 / 312 54 / 89 Handbook of Pharmaceutical Excipients, 2nd edition, 1994.

[0164] Another aspect of this disclosure relates to a method for preparing a pharmaceutical composition, which comprises mixing at least one [11C] radiolabeled antibody-drug conjugate or an antibody-drug conjugate-type compound as defined herein with one or more other pharmaceutically acceptable ingredients (e.g., carriers, diluents and excipients) well known to those skilled in the art. If formulated as discrete units (e.g., tablets), each unit contains a predetermined amount (dose) of the active compound.

[0165] As used in this document, the term pharmaceutically acceptable refers to compounds, ingredients, materials, compositions, dosage forms, etc., that are, within the scope of common medical sense, suitable for contact with the tissue of the subject in question (e.g., a human being), without toxicity, irritation, allergic reactions or other undue problems or complications, which is consistent with a rational benefit / risk ratio. Each vehicle, diluent, excipient, etc. must also be acceptable, in the sense of being compatible with the other ingredients of the formulation.

[0166] Formulations can be prepared by any method well known in the pharmaceutical field. Such methods include the step of combining the active compound with a vehicle that constitutes one or more auxiliary ingredients. Generally, formulations are prepared by uniformly and intimately combining the active compound with a vehicle (e.g., a liquid vehicle or a finely divided solid vehicle) and then shaping the product as required.

[0167] The formulation can be prepared to provide rapid or slow release; immediate, delayed, programmed or sustained release; or a combination thereof.

[0168] Formulations suitable for parenteral administration (e.g., by injection) include sterile aqueous or non-aqueous, isotonic, pyrogen-free liquids (e.g., solutions or suspensions) in which the active ingredient is dissolved, suspended, or otherwise supplied (e.g., in liposomes). Petition 870250101969, dated 07 / 11 / 2025, p. 62 / 312 55 / 89 or other microparticles). Such liquids may additionally contain other pharmaceutically acceptable ingredients, such as antioxidants, buffers, preservatives, stabilizers, bacteriostats, suspending agents, thickeners, and solutes, which can make the formulation isotonic with the blood (or other relevant body fluids) of the intended recipient. Examples of excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, etc. Examples of suitable isotonic vehicles for such formulations include a sodium chloride injection, Ringer's solution, or Ringer's lactate injection. Typically, the concentration of the active ingredient in the liquid ranges from about 1 ng / mL to about 10 μg / mL, for example from about 10 ng / mL to about 1 μg / mL.The formulation may be present in single-dose or sealed multidose containers (e.g., ampoules and vials) and may be stored under freeze-drying conditions (lyophilization), requiring only the addition of a sterile liquid vehicle (e.g., water) for injection (immediately) before use. Temporary injectable solutions and suspensions may be prepared from sterile powders, granules, and tablets. 5. Manufacturing article and kit

[0169] In another aspect, a manufacturing article or kit comprising an anti-PDL1 antibody-drug conjugate described in this document is provided. The manufacturing article or kit may also comprise instructions for use of the anti-PDL1 antibody-drug conjugates described in this document in the methods of this disclosure. Therefore, in certain embodiments, the manufacturing article or kit comprises instructions for use of the anti-PDL1 antibody-drug conjugate described in this document in a method for treating cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, breast cancer (e.g., triple-negative breast cancer (TNBC)), pancreatic cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), esophageal cancer, bladder cancer, cancer Petition 870250101969, dated 07 / 11 / 2025, page 63 / 312 56 / 89 gastric, colorectal cancer, cervical cancer, kidney cancer, prostate cancer, pancreatic cancer and glioma), comprising the method of administering to the subject an effective amount of the anti-PDL1 antibody-drug conjugate described herein. In some embodiments, the subject is a human being.

[0170] The manufacturing article or kit may also comprise a container. Suitable containers include, for example, bottles, vials (e.g., double-compartment vials), injectors (e.g., single-compartment or double-compartment injectors), and test tubes. In some embodiments, the container is a vial. The container may be made of various materials, such as glass or plastic. The container holds the formulation.

[0171] The manufacturing article or kit may also comprise a label or packaging insert on, or attached to, the container, which may indicate instructions for reconstitution and / or use of the formulation. The label or packaging insert may further indicate that the formulation is useful for, or intended for, subcutaneous, intravenous (e.g., intravenous infusion) or other administration to treat cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, breast cancer (e.g., triple-negative breast cancer (TNBC)), pancreatic cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), esophageal cancer, bladder cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, prostate cancer, pancreatic cancer, and glioma) in a subject.The container holding the formulation may be a disposable bottle or a multi-purpose bottle, which allow for repeated administration of the reconstituted formulation. The manufactured article or kit may also comprise a second container containing a suitable diluent. The manufactured article or kit may also comprise other materials desired from a commercial, therapeutic, and user perspective, including other stoppers, diluents, filters, needles, syringes, and packaging inserts printed with instructions for use. Petition 870250101969, dated 07 / 11 / 2025, page 64 / 312 57 / 89

[0172] The article of manufacture or kit in this document also optionally comprises a container containing a second agent, wherein the anti-PDL1 antibody-drug conjugate is a first agent, and the article of manufacture or kit further comprises instructions on a label or packaging insert for treating a subject with an effective amount of the second agent. In some embodiments, the second agent is used to eliminate or reduce the severity of one or more adverse events.

[0173] In some embodiments, the anti-PDL1 antibody-drug conjugate is present in the container as a lyophilized powder. In some embodiments, the lyophilized powder is in a hermetically sealed container, such as a vial, ampoule, or bag, wherein the container indicates the quantity of the active agent. In the case of drug administration by injection, an ampoule of sterile water for injection or normal physiological saline may, for example, be optionally provided as part of the kit so that the ingredients can be mixed before administration. Such kits may also comprise, if desired, one or more of several conventional pharmacological components, such as, for example, a container having one or more pharmaceutically acceptable vehicles, an additional container, etc. This is clear to those skilled in the art.The kit may also include printed instructions such as inserts or labels indicating the quantity of components to be administered, administration guidelines, and / or instructions for mixing the components. Sequence listing SEQ ID NO Gene name Amino acid sequence 1. CDR1 of MAB20 SYTMN heavy chain 2. CDR2 of SISSGSDYLYYADSVKG Petition 870250101969, dated 07 / 11 / 2025, page 65 / 312 58 / 89 MAB20 heavy chain 3. MAB20 heavy chain CDR3 NELRWYPQAGAFDR 4. MAB20 light chain CDR1 SGSSSYIESSYVG 5. MAB20 light chain CDR2 DDDMRPS 6. MAB20 light chain CDR3 EIWRSGLGGV 7. MAB20 heavy chain variable region EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMN WVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQ AGAFDRWGQGTMVTVSS 8. MAB20 light chain variable region QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGW YQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSAT LAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVLS QP 9. Heavy chain of MAB20 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMN WVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQ AGAFDRWGQGTMVTVSSASTKGPSVFPLAPSSKSTS Petition 870250101969, dated 07 / 11 / 2025, page 66 / 312 59 / 89 GGTAALGCLVKDYFPEPPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 10. Cadeia leve de MAB20 QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGW YQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSAT LAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVLS QPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVT VAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLT PEQWKSHKSYSCQVTHEGSTVERTVALTEC 11. ECD do PDL1 humano FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVY WEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQL SLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVK VNAPYNKINQRILVVDPVTSEHELTCQAEGYKPAEVI WTSSDHQVLSGKTI IINSKREEKLFNVISILRINI II NEIFYCTFRRLDPEENHTAELVIPELPLAHPPNER 12.Monkey PDL1 ECD FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLTSLIVY WEMEDKNIIQFVHGEEDLKVQHSNYRQRAQLLKDQL SLGNAALRIIDVKLQDAGVYRCMISYGGADYKRIIVK VNAPYNKINQRILVVDPVISEHELICQAEGYPKAEVI WISSDHQVLSGKII IINSKREEKLLNVTSTLRINTTA NEIFYCIFRRLDPEENHTAELVIPELPLALPPNERTH 13. FTITAPKDLYVVEYGSNVTMECRFPVEQKLDLLALVV YWEKEDKEVIQFVEGEEDLKPQHSSFRGRAFLPKDQ PDL1 ECD. Petition 870250101969, dated 07 / 11 / 2025, page 67 / 312 60 / 89 Mouse LLKGNAVLQITDVKLQDAGVYCCMISYGGADYKRITLK VNAPYRKINQRISMDPATSEHELMCQAEGYPEAEVIW TNSDHQSLSGETTVTTSQTEEKLLNVTSVLRVNATAN DVFHCTFWRVHSGENHTAELIIPELPVPRLPHNRTH FTITAPKDLYVVEYGSNVTMECRFPVERELDLLALVVY WEKEDEQVIQFVAGEEDLKPQHSNFRGRASLPKDQL LKGNAALQITDVKLQDAGVYCCIISYGGADYKRITLKV NAPYRKINQRISVDPATSEHELICQAEGYPEAEVIWTN SDHQPVSGKRSVTTSRTEGMLLNVTSSLRVNATAND VFYCTFWRSQPGQNHTAELIIPELPATHPPQNRTH 15. Heavy chain of the SGN antibody fraction PDL1V QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAAISW VRQAPGQGLEWMGGIIPIFGKAHYAQKFQGRVTITAD ESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFG MDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK 16.Light chain of the SGN antibody fraction PDL1V EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ QKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI SSLEPEDFAVYYCQQRSNWPTFGQGTKVEIKRTVAA PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC. Petition 870250101969, dated 07 / 11 / 2025, p. 68 / 312 61 / 89 Examples

[0174] This disclosure will be further described in the following examples, which should not be interpreted as a limitation to the present disclosure. Reagents and materials:

[0175] Organic solvents such as dimethyl sulfoxide were purchased from Spectrum Chemical Mfg Corp and TCEP-HCl reagent from Thermo Fisher, etc.

[0176] IgG1 is an acquired isotype control from Beijing Sino Biological, Inc.

[0177] The pH-sensitive Zenon™ pHrodo™ iFL IgG labeling reagent was purchased from Thermo Fisher.

[0178] The CellTiter-Glo solution was acquired from Promega.

[0179] The cell strains NCI-H292, BXPC-3 (for in vivo models) and MDA-MB231 were acquired from the Chinese Academy of Sciences Cell Bank, NCIH441 was acquired from ATCC and BXPC-3 (for in vitro cell death) was acquired from Wuhan Pricella Biotechnology Co., Ltd., and several PDX transplants were established and maintained by Shanghai Lide Biotech Co., Ltd. Preparatory plan:

[0180] The structures of the compounds described in the following examples were determined by hydrogen nuclear magnetic resonance spectroscopy (1H NMR) or liquid chromatography-mass spectrometry (LCMS).

[0181] A Bruker 400 MHz nuclear magnetic resonance instrument was used for the determination of hydrogen nuclear magnetic resonance spectroscopy (1H NMR); the solvents for the determination were deuterated methanol (CD3OD), deuterated chloroform (CDCl3) or hexadeuterated dimethyl sulfoxide (DMSO-d6); and the internal standard substance was tetramethylsilane (TMS).

[0182] The abbreviations used in the nuclear magnetic resonance (NMR) spectra of the examples are shown below.

[0183] s: singlet; d: doublet; t: triplet; q: quartet; dd: doublet of a doublet; qd: quartet of a doublet; ddd: doublet of a doublet of a doublet; ddt: doublet of a doublet Petition 870250101969, dated 07 / 11 / 2025, page 69 / 312 62 / 89 triplet; dddd: doublet of doublet of doublet of doublet; m: multiplet; br: broadened signal; J: coupling constant; Hz: Hertz; DMSO-d6: deuterated dimethyl sulfoxide. Δ values ​​were expressed in ppm.

[0184] Liquid chromatography-mass spectrometry (LC-MS) detection was carried out using an Agilent model Agilent 6120B mass spectrometer (ESI). Example 1. Preparation of the toxin-binding agent (LP62) LP62 Example 1.1: synthesis of (S)-7-ethyl-7-hydroxy-14-(3-hydroxypropyl)-10,13-dihydro-11H-[1,3]dioxolo[4,5-g]pyrano[3',4',6,7]indolizino[1,2-b]quinoline8,11(7H)-dione (A1.3)

[0185] The synthetic route for compound A1.3 is as shown in Scheme 1 below: Scheme 1: Preparation of the active compound A1.3

[0186] The specific steps were as follows: Petition 870250101969, dated 07 / 11 / 2025, page 70 / 312 63 / 89 A 1.1 A 1.2

[0187] Step 1: Under ice bath conditions, ferrous sulfate heptahydrate (570 mg of ferrous sulfate heptahydrate dissolved in 1 mL of water) and 4,4-dimethoxychlorobutane (3.89 g) were added to a solution of (S)-7-ethyl-7hydroxy-10,13-dihydro-11 / 7-[1,3]dioxolo[4,5-g]pyrano[3',4',6,7]indolizino[1,2b]quinolino-8,11(7 / 7)-dione (A1.1, 500 mg) in 75% sulfuric acid (5 mL). The reaction liquid was stirred for three minutes and then hydrogen peroxide (29%, 2.5 mL) was added dropwise under ice bath conditions. After the dropwise addition was complete, the reaction liquid was reacted under stirring at 0 °C for 5 minutes, then heated to room temperature and reacted under stirring for 3 hours. The reaction liquid was diluted with water (50 mL) and extracted with ethyl acetate (80 mL χ2). The organic phase was washed with a saturated aqueous solution of sodium chloride and then dried with anhydrous sodium sulfate.The organic phase was evaporated under reduced pressure and then concentrated to give a crude product, which was purified using preparative liquid chromatography fitted with a C18 column (acetonitrile / aqueous formic acid solution at 0.05%; 5% up to 60%) to finally give the target compound (A1.2, as a yellow solid, 400 mg, yield: 67%).

[0188] LC-MS (ESI) [M+H]+: 468.9: 1HNMR (400 Hz, DMSO-c / 6) 07.65 (s,1H), 7.51 (s,1H),7.24 (s, 1H), 6.50 (s,1H), 6.30 (s, 2H), 5.42 (s, 2H), 5.26 (s, 2H), 3.81 (d, J = 5.9 Hz, 2H), 3.22 (s, 2H), 1.98 (d, J = 6.7 Hz, 4H), 0.88(t, J = 7.2 Hz, 3H). Petition 870250101969, dated 07 / 11 / 2025, p. 71 / 312 64 / 89 A 1.2 A 1.3

[0189] Step 2: (S)-7-ethyl-7-hydroxy-14-(3-chloropropyl)-10,13-dihydro11H-[1,3]dioxolo[4,5-g]pyrano[3',4',6,7]indolizino[1,2-b]quinolino-8,11(7H)-dione (A1.2, 100 mg, 0.213 mmol) was dissolved in a 10% sulfuric acid solution (5 mL) and the reaction liquid was reacted at 110 °C for 48 hours. A saturated sodium bicarbonate solution (30 mL) was added to the reaction liquid and the reaction liquid was extracted with dichloromethane (10 mL χ 5), dried with anhydrous sodium sulfate, filtered by suction and concentrated under reduced pressure to give a crude product. The crude product was subjected to preparative purification by high-performance liquid chromatography (acetonitrile / water, with 0.05% formic acid) to give (S)-7-ethyl-7-hydroxy-14-(3-hydroxypropyl)-10,13-dihydro-11H[1,3]dioxolo[4,5-g]pyrano[3',4',6,7]indolizino[1,2-b]quinolino-8,11(7H)-dione (A1.3, 1.78 mg).

[0190] LC-MS (ESI) [M+H]+: 451.0: 1HNMR (400 Hz, DMSO-c / 6) δ7.63 (s,1H), 7.50 (s,1H),7.24 (s, 1H), 6.48 (s,1H), 6.28 (s, 2H), 5.47-5.37 (m, 2H), 5.32-5.19 (m, 2H), 3.51-3.46 (m, 2H), 3.17-3.13 (m, 2H), 1.92-1.76 (m, 4H), 0.90-0.84 (m, 3H). Example 1.2: synthesis of compound A2.3

[0191] The synthetic route for compound A2.3 is as shown in Scheme 2 below: Petition 870250101969, dated 07 / 11 / 2025, page 72 / 312 65 / 89 Scheme 2: synthetic pathway of compound A2.3

[0192] The specific steps for the synthesis of compound A2.3 were as follows

[0193] Step 1: Compound A2.1 (368 mg), compound A1.3 (440 mg) and pyridinium ptoluenesulfonate (PPTS, 25 mg) were refluxed in dichloromethane (20 mL) at 40 °C for 20 hours and then washed separately with an aqueous solution of sodium bicarbonate and an aqueous solution of hydrochloric acid, the organic solvent being removed under reduced pressure to give a crude product. The crude product was separated and purified by column chromatography (dichloromethane:methanol = 10:1) to give the target compound A2.2 (240 mg).

[0194] LC-MS (ESI) [M+H]+: 747: Petition 870250101969, dated 07 / 11 / 2025, page 73 / 312 66 / 89

[0195] Step 2: A2.2 (240 mg) was dissolved in DMF (5 mL) and piperidine (1 mL) was added. The mixture was stirred at room temperature for 20 minutes. The low-boiling-point components were removed under pressure and the residue was used directly in the next synthesis step. A small amount of the crude product was purified by reverse-phase chromatography (acetonitrile / AF (formic acid) at 0.05% in water: 5% to 50%) to give the target compound A2.3.

[0196] LC-MS (ESI) [M+H]+: 525: 1H NMR (400 Hz, DMSO-d6) 59.13 (t,1H), 8.04 (I, 2H), 7.58 (s, 1H), 7.51 (s, 1H), 7.25 (s, 1H), 6.29 (s, 2H), 5.43 (s, 2H), 5.21 (s, 2H), 4.65 (d, 2H), 3.63 (m, 2H), 3.53 (m, 2H), 3.11 (m, 2H), 1.87 (m, 4H), 0.88 (t, 3H). Example 1.3: synthesis of compound A3.5

[0197] The synthetic route for compound A3.5 is as shown in Scheme 3 below: A3.1 Scheme 3: synthetic pathway of compound A3.5

[0198] The specific synthetic steps for compound A3.5 were as follows: Petition 870250101969, dated 07 / 11 / 2025, p. 74 / 312 67 / 89 \^O^NH NH2 I o A3.1 A3.2

[0199] Step 1: a hydrogen chloride-dioxane solution (dioxane, C4H8O2) (100 mL) was added to compound A3.1 (10.0 g) and the mixture was reacted at room temperature for 2 hours. The reaction liquid was concentrated under reduced pressure to give the target compound A3.2 (8.0 g) as a white solid.

[0200] LC-MS (ESI) [M+H]+: 380.11H NMR (400 MHz, DMSO-c / 6) δ 8.18 (d, J = 7.4 Hz, 1H), 7.40-7.30 (m, 5H), 7.26 (d, J = 8.8 Hz, 1H), 5.08-4.99 (m, 2H) 17.3, 6.6 Hz, 6H). A3.2 A3.3

[0201] Step 2: Compound A3.2 (5.0 g, 12 mmol) was dissolved in dichloromethane (100 mL) and n-propanal (4.2 g, 72.3 mmol) was added to the reaction liquid. The reaction was stirred at room temperature for 10 minutes, and then sodium triacetoxyborohydride (12.8 g, 60.25 mmol) was added to the reaction liquid. The reaction was stirred at room temperature for 1 hour. LC-MS showed that the reaction was complete. A saturated aqueous solution of ammonium chloride was added to the reaction liquid and stirred for 1 hour. After rotary drying and filtration, the filtrate was purified by reverse separation using a C18 column to give the target compound A3.3 (4.57 g, yield 82.0%). Compound A3.3 was a white solid. Petition 870250101969, dated 07 / 11 / 2025, page 75 / 312 68 / 89

[0202] LC-MS (ESI) [M+H]+: 464.0: 1H NMR (400 MHz, DMSO-c / 6) δ 7.81 (d, J = 7.3 Hz, IH), 7.38-7.28 (m, 5H), 5.04 (d, J = 1.7 Hz,2H),4.12- 4.02 (m, IH), 3.94-3.82 (m, 1H), 2.65-2.52 (m, 6H), 2.061.94 (m, 1H), 1.76-1.64 (m, 1H), 1.64-1.53 ​​(m, 1H), 1.52-1.40 (m, 6H), 1.34-1.18 (m, 2H), 0.92-0.80 (m, 12H).

[0203] Step 3: Compound 3.3 (2.0 g, 4.32 mmol) was dissolved in methanol (80 mL) at room temperature and then Pd / C (0.16 g) was added to the reaction liquid. The reaction was stirred at room temperature under nitrogen for 12 hours. After LC-MS showed that the reaction was complete, the reaction liquid was filtered and concentrated under reduced pressure to give the target compound A3.4 (1.2 g, 85.5% yield) as a white solid. A3.4 A3.5

[0204] Step 4: 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-inoic acid (100 mg, 0.373 mmol) was dissolved in DMF (1 mL), and then HATU (142 mg, 0.373 mmol) and Λ / , / V-diisopropylethylamine (120 mg, 0.93 mmol) were added. The system was stirred for 30 minutes, and compound A3.4 (122 mg, 0.371 mmol) was then added. The reaction liquid was stirred at room temperature for 1 hour. After the reaction was complete, as detected by LC-MS, the reaction liquid was directly purified by reverse-phase chromatography on a C18 column (0.05% aqueous formic acid and acetonitrile solution system) to obtain the target compound N^N6-dipropyl-N2-((6-(2-(methylsulfonyl)pyrimidin-5 Petition 870250101969, dated 07 / 11 / 2025, page 76 / 312 69 / 89 yl)hex-5-inoyl)-L-valine)-L-lysine (compound A3.5, 50 mg, 28% yield) as a pale yellow solid.

[0205] LC-MS (ESI) [M+H]+: 580.0: 1HNMR (400 MHz, DMSO-c / 6) δ 8.24 (s, 2H), 7.98-7.93 (m, 2H), 4.24-4.16 (m, 1H), 4.10 (d, J = 5.2Hz, 1H), 3.41 (s, 3H), 2.79-2.64 (m, 6H), 2.55 (t, J = 7.1Hz, 2H), 2.45-2.26 (m, 2H), 2.06-1.91 (m, 1H),1.89-1.78 (m, 2H), 1.76-1.66 (m, 1H), 1.641.57 (m, 1H), 1.57-1.42 (m, 6H). 1.37-1.24 (m, 2H), 0.93-0.78 (m, 12H). Example 1.4: Synthesis of the toxin-linker (LP62)

[0206] Step 1: Compound A3.5 (43 mg, 0.074 mmol) and compound A2.3 (40 mg, 0.074 mmol) were dissolved in 1 mL of DMF, and then HBTU (28 mg, 0.075 mmol) and / V, / V-diisopropylethylamine (24 mg, 0.187 mmol) were added sequentially. The reaction liquid was stirred at room temperature for 1 hour. After the reaction was complete, as detected by LC-MS, the reaction liquid was directly purified by preparative chromatography (a 0.01% aqueous solution of trifluoroacetic acid, acetonitrile) to give the target compound. Petition 870250101969, dated 07 / 11 / 2025, p. 77 / 312 70 / 89 LP62 as a trifluoroacetate salt (8.5 mg, 10% yield) in the form of a yellow solid.

[0207] LC-MS (ESI) [M+H]+: 1098.6: 1H NMR (400 MHz, DMSO-d6): δ 9.10 (s, 2H), 9.03 (s, 1H), 8.64 (t, J = 6.4 Hz, 1H), 8.19 (m, J = 5.9 Hz, 1H), 8.08 (d, J = 7.4 Hz, 1H), 7.92 (d, J = 8.5Hz,1H), 7.59 (s, 1H), 7.51 (s, 1H), 7.24 (s, 1H), 6.49 (s, 1H), 6.29 (s, 2H), 5.42 (s, 2H), 5.24 (s, 2H), 4.66-4.52 (m, 2H), 4.31-4.21 (m, 1H), 4.19-4.10 (m, 1H), 3.74 (d, J= 5.5 Hz, 2H), 3.49-3.48 (m,2H),3.40 (s, 3H), 3.15-3.06 (m,2H), 3.02-2.95 (m,6H), 2.59-2.52 (m, 3H), 2.41-2.29 (m, 2H), 2.50-1.90 (m, 2H), 1.91-1.77 (m, 6H), 1.63-1.57 (m, 6H), 1.31-1.29 (m,2H), 0.92-0.80 (m,15H). Example 2. Antibody preparation

[0208] Unless otherwise indicated, the amino acid sequences of the heavy chain and light chain of the anti-PDL1 antibody used in this disclosure are described in the Sequence Listing.

[0209] In general, the antibody was prepared as follows: A stable CHO cell line was constructed that expressed and secreted an anti-PDL1 antibody. The stable CHO cell line was cultured in a suitable culture medium. A culture supernatant was collected and sequentially subjected to depth filtration, protein A column affinity chromatography, virus inactivation, filtration, anionic chromatography, cationic chromatography, nanofiltration / ultrafiltration, and other processes. Finally, a target antibody was obtained. Example 3. Preparation and detection of antibody-drug conjugates Example 3.1. Preparation of MAB20-LP62 where n = 8, indicating the molar ratio between the loaded binder and drug. Petition 870250101969, dated 07 / 11 / 2025, page 78 / 312 71 / 89 and the antibody.

[0210] 2 to 5 mL of anti-PDL1 MAB20 antibody (AntiPDL1_mAb, 10 to 30 mg / mL) were placed in a specific antibody conjugation reactor. EDTA was added to a final concentration of 10 to 20 mM, and the pH was then adjusted between 5.5 and 7.5 with a 0.5 to 1 M disodium hydrogen phosphate solution. 10 to 20 mM TCEP (tris(2-carboxyethyl)phosphine, 4 to 10 eq., 0.1 to 0.8 mL) was slowly added, the mixture was mixed uniformly and reacted at room temperature for 50 to 80 minutes. After the anti-PDL1 antibody reduction reaction was complete, a solution of LP62 toxin-binding agent (8 to 15 eq., 2 to 10 pmol) previously dissolved in dimethyl sulfoxide (DMSO) or DMAC solvent was added to the above solution system, the system was stirred, mixed uniformly and reacted at room temperature for 100 to 150 minutes.After purification by cationic chromatography, the system buffer was then replaced with 20 to 50 mM PB, pH 5.5 to 7.5 using Amicon Ultra-15 to give MAB20-YL62, a conjugated product of the anti-PDL1 antibody MAB20 and the toxin-binding agent LP62. The DAR value and monomer content were verified by LC-MS, HIC and HPLC-SEC analysis, and met the standards. Example 3.2. Preparation of the MAB20-VC-MMAE reference ADC Structure of MAB20-VC-MMAE (where Ac was MAB20 and k was the value of DAR)

[0211] MAB20-VC-MMAE was prepared according to a general method in the state of the art. Specifically, 2 to 5 mL of the antibody against PDL1 MAB20 (Anti-PDL1_mAb, 10 to 30 mg / mL) were placed in a specific reactor for antibody conjugation. EDTA was added to a final concentration of 10 Petition 870250101969, dated 07 / 11 / 2025, page 79 / 312 72 / 89 to 20 mM, and the pH was then adjusted between 5.5 and 7.5 with a 0.5 to 1 M disodium hydrogen phosphate solution. 10 to 20 mM TCEP (tris(2-carboxyethyl)phosphine, 2 to 4 eq., 0.1 to 0.8 mL) was slowly added, the mixture was mixed uniformly and reacted at room temperature for 50 to 80 minutes. After the MAB20 reduction reaction was complete, a solution of MC-VC-PAB-MMAE ligand toxin (whose structure was as shown below) (4 to 15 eq., 1 to 10 μmol) previously dissolved in a dimethyl sulfoxide (DMSO) or DMAC solvent was added to the above solution system, the system was stirred, mixed uniformly and left at room temperature for 100 to 150 minutes. After purification by cationic chromatography, the system buffer was replaced with 20 to 50 mM PB, pH 5.5 to 7.5 using Amicon Ultra-15 to give MAB20-VC-MMAE, a conjugated product of the anti-PDL1 antibody MAB20 and MC-VC-PAB-MMAE.The DAR value and its monomer content were verified by LC-MS, HIC, and HPLC-SEC analysis, and met the standards. NH NH2 MC-VC-PABC-MMAE Sample Name | Aggregate (%) | Main Peak (%) | Fragment (%) | MAB20-VC-MMAE | 0.8 | 98.6 | 0.6 Sample Name | DAR Chain for LC / HC | DAR for IgG | MAB20-VC-MMAE | LC (light chain) 0.6 4.00 | HC (heavy chain) 1.40 DAR value for the anti-PDL1-drug antibody conjugate sample Example 3.3. Preparation of the SGN-PDL1V reference ADC Petition 870250101969, dated 07 / 11 / 2025, page 80 / 312 73 / 89 Structure of SGN-PDL1V (where Ac was the antibody fraction of SGN-PDL1V and k was the DAR value)

[0212] SGN-PDL1V can be prepared by reference to the method described in WO 2021067776 A1. Alternatively, it can be prepared as follows: 2 to 5 mL of the SGN-PDL1V antibody fraction (10 to 30 mg / mL) were placed in a specific reactor for antibody conjugation. EDTA was added to a final concentration of 10 to 20 mM, and the pH was then adjusted between 5.5 and 7.5 with a 0.5 to 1 M disodium hydrogen phosphate solution. 10 to 20 mM TCEP (tris(2-carboxyethyl)phosphine, 2 to 4 eq., 0.1 to 0.8 mL) was slowly added, the mixture was mixed uniformly and reacted at room temperature for 50 to 80 minutes. After the antibody reduction reaction was complete, a solution of MC-VC-PAB-MMAE toxin-binding solution (whose structure was as shown below) (4 to 15 eq.A concentration (1 to 10 pmol) previously dissolved in a dimethyl sulfoxide (DMSO) or DMAC solvent was added to the above solution system. The system was then stirred, uniformly mixed, and left at room temperature for 100 to 150 minutes. After purification by cationic chromatography, the system buffer was replaced with 20 to 50 mM PB, pH 5.5 to 7.5 using Amicon Ultra-15 to yield SGN-PDL1V, a conjugated product of the antibody fraction of SGN-PDL1V and MC-VC-PAB-MMAE. The DAR (DAR4) value and monomer content were verified by LC-MS, HIC, and HPLC-SEC analysis, and met the standards. Petition 870250101969, dated 07 / 11 / 2025, page 81 / 312 74 / 89 MC-VC-PABC-MMAE Example 3.4. Preparation of the MAB20-GGFG-DXD reference ADC Structure of MAB20-GGFG-DXD (where Ac was MAB20 and k was the value of DAR)

[0213] MAB20-GGFG-DXD was prepared according to a general method in the state of the art. Specifically, 2 to 5 mL of the anti-PDL1 antibody MAB20 (Anti-PDL1_mAb, 10 to 25 mg / mL) were taken and placed in a reaction tube. EDTA was added to a final concentration of 10 to 20 mM, and the pH was then adjusted between 6.0 and 7.5 with a 0.5 to 1 M disodium hydrogen phosphate solution. 10 to 20 mM TCEP (tris(2-carboxyethyl)phosphine, 4 to 10 eq., 0.1 to 0.4 mL) was slowly added, the mixture was mixed uniformly and reacted at room temperature for 50 to 80 minutes. After the MAB20 reduction reaction was complete, a solution of MC-GGFG-DXD toxin-binding agent (whose structure was as shown below) (8 to 12 eq., 2 to 10 pmol) previously dissolved in a dimethyl sulfoxide (DMSO) or DMAC solvent was added to the above solution system, the system was stirred, mixed uniformly and left at room temperature for 100 to 150 minutes.The system buffer was replaced with PB 10 to 50 mM or histidine-histidine hydrochloride, pH 5.5 to 7.5. Petition 870250101969, dated 07 / 11 / 2025, page 82 / 312 75 / 89 using Amicon Ultra-15 to give MAB20-GGFG-DXD, a conjugated product of MAB20 and the toxin-binding MC-GGFG-DXD. The DAR value and monomer content were verified by LC-MS, HIC and HPLC-SEC analysis, and met the standards. MC-GGFG-DXD Example 3.5: Analysis of the antibody-drug conjugate by LC-MS regarding the drug-to-antibody ratio (DAR)

[0214] A sample of antibody-drug conjugate was reduced with DTT at 37 °C for 10 minutes and the DAR value of the conjugate was then analyzed using LC-MS. Specifically, the reduced sample was injected into an LC-MS system (Agilent 1290 Infinity II and Agilent 6545XT AdvanceBio Q-TOF LC systems) equipped with an Acquity C4 reversed-phase UPLC column with BEH (Waters Corporation, 2.1 mm χ 50 mm, 1.7 μm, 300 Å). The drug:antibody ratio (DAR) was calculated using the provided devolved LC-MS results. Example 4. Affinity assay of the anti-PDL1 antibody-drug conjugate by PDL1-positive cells

[0215] Normally cultured and subcultured NCI-H292 and NCI-H441 tumor cells were collected, washed with PBS, resuspended, and inoculated into a 96-well plate at 1 χ¹⁰⁶ cells / well / 50 μL, respectively. The test sample was then diluted with a gradient using, for example, a FACS buffer (PBS + 2% FBS), and after dilution, the test sample and the control sample were sequentially added to the 96-well plate. Petition 870250101969, dated 07 / 11 / 2025, page 83 / 312 76 / 89 inoculated with cells, where the IgG1 control sample was a human IgG1 isotype control, κ (acquired from Beijing Sino Biological, Inc.). The sample plate was incubated at 4 °C for 0.5 h, centrifuged, followed by supernatant removal and washing with 300 μL / well of FACS buffer. Subsequently, a fluorescently labeled goat anti-human IgG antibody detection solution was added to the sample plate (100 μL / well) sequentially for incubation with the cells. The sample plate was incubated at 4 °C for 0.5 h, washed with 300 μL / well of FACS buffer, and finally the cells were resuspended. The numerical value of fluorescence for each sample was detected by a flow cytometer. The data were analyzed in Graphpad Prism 8.1 and fitted to a four-parameter equation.

[0216] As shown in FIG. 1A, MAB20-LP62 (DAR8) exhibited better affinity for PDL1-positive NCI-H292 cells and its affinity was comparable to that of the unconjugated MAB20 antibody. Similarly, as shown in FIG. 1B, MAB20-LP62 (DAR8) exhibited better affinity for PDL1-positive NCI-H441 cells. Example 5. Internalization assay of the anti-PDL1 antibody-drug conjugate in PDL1-positive cells

[0217] A volume of normally cultured and subcultured NCI-H292 cells was collected and centrifuged, followed by removal of the supernatant and resuspension in a cell culture medium (RPMI-1640 culture medium + 10% FBS). 50 μL of the cell suspension were inoculated into a 96-well plate for use (1 χ² 10⁵ cells / well). A pH-sensitive Zenon™ pHrodo™ iFL IgG labeling reagent (purchased from ThermoFisher) was formulated with the cell culture medium to form the 1 4x (480 nM) working solution. This pH-sensitive dye conjugate did not fluorescent extracellularly but exhibited strong fluorescence in an acidic environment, including lysosomes. The test material was formulated with cell culture medium to form working solution 2 4x (160 nM). 25 μL of working solution 1 and 25 μL of working solution 2 were collected separately and Petition 870250101969, dated 07 / 11 / 2025, page 84 / 312 77 / 89 added to a 96-well plate, followed by mixing and incubation. The mixed liquid was pipetted into 50 μL of the cell suspension, mixed uniformly, and placed in an incubator for culture. At time points of 0, 2, 16, and 24 h, test materials were collected and centrifuged, and the supernatants were removed. The resulting material was then washed with 300 μL / well of FACS buffer and resuspended, and the fluorescence value of each sample was measured using a flow cytometer.

[0218] As shown in FIG. 2, compared with the IgG1 isotype control data, the internalization ratio of MAB20-LP62 (DAR8) and MAB20 increased as the incubation time increased and peaked at 4 h, indicating that the anti-MAB20 antibody-drug conjugate MAB20-LP62 (DAR8) can effectively bind to PDL1 antigen on the cell surface and be internalized via the intracellular lysosomal pathway. Example 6. Assay of the cell death activity of the anti-PDL1 antibody-drug conjugate

[0219] Cells in the exponential growth phase were collected and viable cells were counted using a Vi-Cell XR cytometer. The cell suspension was adjusted to an appropriate concentration with a culture medium. The 80 pL / well cell suspension was added to a cell culture plate. The test sample was diluted with a gradient (5-fold dilutions). 20 pL of each of the diluted test items were collected and added to the cell suspension in the cell culture plate, and the cell culture plate was placed in an incubator and cultured for 72 hours. After 72 hours, a 50 pL / well CellTiter-Glo solution (purchased from Promega) that had been previously thawed and equilibrated to room temperature was added according to the CellTiter-Glo operating instructions. The wells were mixed uniformly with a microwell plate shaker for 2 minutes and held at room temperature for 10 minutes.The fluorescence signal was measured using the Envision 2104 plate reader. The raw data were analyzed using Graphpad Prism 8.1 and fitted to a four-factor equation. Petition 870250101969, dated 07 / 11 / 2025, page 85 / 312 78 / 89 parameters.

[0220] As shown in FIG. 3, MAB20-LP62 (DAR8) showed stronger cell death effects in MAB20-insensitive PDL1-positive NCI-H292, BXPC3 and NCI-H441 tumor cells. Example 7. Cross-linking activity of the anti-PDL1drug antibody conjugate to PDL1s of different species.

[0221] The extracellular domains (ECDs) of PDL1s derived from humans, cynomolgus monkeys, rats, and mice were separately diluted with 1x PBS to a working concentration of 2 pg / mL, as ELISA coating solutions. The test plate was washed 3 times with PBST (PBS with 0.05% Tween 20). The plate was incubated with a SuperBlock T20 (PBS) Blocking Buffer solution (60 pL / well) at room temperature, the test sample was then diluted with a gradient, and the diluted samples were then loaded separately onto a test plate and incubated at room temperature. The test plate was washed, and HRP enzyme-labeled goat anti-human IgG antibody was added as a secondary antibody, followed by incubation. The test plate was washed, and a stopping solution (30 pL / well) was added, followed by centrifugation. The absorbance of light was measured at a wavelength of 450 nm.The raw data were analyzed using Graphpad Prism 8.1 and fitted to a four-parameter equation.

[0222] As shown in FIG. 4, the binding affinity of MAB20-LP62 for cynomolgus and mouse PDL1 ECDs was close to that of human PDL1 ECD, with EC50 values ​​of 0.039 nM, 0.094 nM, and 0.054 nM, respectively. MAB20LP62 (DAR8) showed weak specific binding to rat PDL1 ECD. Example 8. Assay of the bystander effect of the anti-PDL1 antibody-drug conjugate

[0223] MDA-MB-468 PDL1-negative tumor cells in the exponential growth phase were collected and viable cells were counted using a Vi-Cell XR cytometer. The cell suspension was adjusted to an appropriate concentration with a culture medium. The cell suspension at 80 pL / well was Petition 870250101969, dated 07 / 11 / 2025, page 86 / 312 79 / 89 added to a cell culture plate. The test drug was diluted with a gradient (5-fold dilutions). 20 μL of each of the diluted test items were collected and added to the cell suspension in the cell culture plate, which was then placed in an incubator and cultured for 96 hours. According to the CellTiterGlo operating instructions, a CellTiter-Glo solution (purchased from Promega) at 50 μL / well, previously thawed and equilibrated to room temperature, was added. The wells were mixed uniformly with a microwell plate shaker for 2 minutes and held at room temperature for 10 minutes. The fluorescence signal was measured using the Envision 2104 plate reader.

[0224] HEK293 cells overexpressing PDL1 in the exponential growth phase were collected, and viable cells were counted using a Vi-Cell XR cytometer. The cell suspension was adjusted to an appropriate concentration with a culture medium. The cell suspension at 80 μL / well was added to a cell culture plate. The test drug was diluted with a gradient (5-fold dilutions). 20 μL of each of the diluted test articles were collected and added to the cell suspension in the cell culture plate, which was then placed in an incubator and cultured for 96 hours. After 96 hours, a conditioned medium supernatant of HEK293 cells overexpressing PDL1 was collected and transferred in an equal volume to MDA-MB-468 cell culture.After continuous cultivation for 96 hours, a 50 μL / well solution of CellTiter-Glo (purchased from Promega) that had been previously thawed and equilibrated to room temperature was added according to the CellTiter-Glo operating instructions. The wells were uniformly mixed with a microwell plate shaker for 2 minutes and held at room temperature for 10 minutes. The fluorescence signal was measured using the Envision 2104 plate reader.

[0225] As shown in FIGS. 5A and 5B, MAB20-LP62 (DAR8) had a significant bystander effect. Example 9. Immunotoxicity assay of the anti-PDL1 antibody conjugate. Petition 870250101969, dated 07 / 11 / 2025, page 87 / 312 80 / 89 drug

[0226] Given that some human immune cells, such as antigen-presenting cells (macrophages, dendritic cells, etc.) express PDL1, the immunotoxicity of PDL1-targeted antibody conjugate drugs is an unavoidable problem. Human dendritic cells and macrophages, after induced differentiation, were digested and viable cells were counted using a Vi-Cell XR cytometer. The cell suspension was adjusted to an appropriate concentration with a culture medium. The cell suspension at 80 pL / well was added to a cell culture plate, which was supplemented with IFN-γ at 500 IU / mL. The test drug was diluted with a gradient (5-fold dilutions). 20 pL of each of the diluted test items were collected and added to the cell suspension in the cell culture plate, and the cell culture plate was placed in an incubator and cultured for 96 hours.A solution of CellTiter-Glo (purchased from Promega) at 50 pL / well, previously thawed and equilibrated to room temperature, was added according to CellTiter-Glo operating instructions. The wells were uniformly mixed with a microwell plate shaker for 2 minutes and held at room temperature for 10 minutes. The fluorescence signal was measured using the Envision 2104 plate reader. SGN-PDL1V was used as one of the control molecules, as disclosed in US patent no. US 20210101982 A1.

[0227] As shown in FIGS. 6 and 7, the control molecule SGN-PDL1V exhibited similar immunotoxicity in macrophages and dendritic cells in vitro compared to the isotypic control ADC (IgG1-MMAE); however, when the concentration was above 20 nM, SGN-PDL1V resulted in nonspecific death of both immune cells. In contrast, MAB20-LP62 (DAR8) did not show significant cytotoxicity to macrophages and dendritic cells, even at high concentrations (500 nM). As a result, MAB20-LP62 had negligible immunotoxicity and greater safety compared to SGNPDL1V. Petition 870250101969, dated 07 / 11 / 2025, page 88 / 312 81 / 89 Example 10. Antitumor activity of the anti-PDL1 antibody-drug conjugate in the NCG mouse model subcutaneously inoculated with MDA-MB-231 human breast cancer cells.

[0228] MDA-MB-231 cells were cultured in a growth culture medium (RPMI 1640 + 10% FBS + IL15). Cells in the logarithmic growth phase were collected, washed twice with DPBS, and used for inoculation. The cells were resuspended with PBS and Matrixgel matrix in a 1:1 ratio, with MDA-MB-231 cells (5 x 10⁶ / 100 μL / mouse) being inoculated subcutaneously on the right back of mice aged 6 to 7 weeks. Once the tumor had grown to an average volume of 204.54 mm³, the mice were randomly grouped depending on tumor size and measured, ensuring similar tumor volumes between groups. The grouping day was defined as day 0. After the start of dosing, the body weight and tumor size of the mice were determined twice a week, and the mice were dosed once a week for three doses. The clinical symptoms observed during the experiment were recorded.The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0229] As shown in FIG. 8, on day 35 post-dose, compared with the control group (MAB20, 8 mg / kg, tumor growth inhibition rate (TGI) 21.26%), MAB20-LP62 (DAR4) (3 mg / kg and 8 mg / kg) and MAB20-LP62 (DAR8) (3 mg / kg and 8 mg / kg) both showed significant tumor growth inhibition, with TGIs of 46.89% (p < 0.001), 74.50% (p < 0.001), 80.33% (p < 0.001) and 92.91% (p < 0.001), respectively. MAB20-LP62 (DAR8) exhibited significant antitumor effects at low doses. Compared to the antibody-drug conjugates MAB20-VC-MMAE (DAR4) (3 mg / kg, ICT of 38.79%) and MAB20-GGFG-DXD (DAR8) (3 mg / kg, ICT of 44.60%; 8 mg / kg, ICT of 72.98%) constructed using a state-of-the-art conjugation technique, MAB20-LP62 (DAR8) showed significantly greater antitumor activity. Petition 870250101969, dated 07 / 11 / 2025, page 89 / 312 82 / 89 excellent. None of the animals showed significant loss of body weight throughout the treatment period. Example 11. Antitumor activity of the anti-PDL1 drug antibody conjugate in the NCG mouse model subcutaneously inoculated with BxPC3 human pancreatic cancer cells with low PDL1 expression.

[0230] BXPC3 cells were cultured in a growth culture medium (RPMI 1640 + 10% FBS). Cells in the logarithmic growth phase were collected, washed twice with DPBS, and used for inoculation. The cells were resuspended with PBS and Matrixgel matrix in a 1:1 ratio. BXPC3 cells (5 x 10⁶ / 100 μL / mouse) were inoculated subcutaneously into the right back of 7-8 week old mice. Once the tumor had grown to an average volume of 210.90 mm³, mice were randomly grouped according to tumor size and dosed, ensuring similar tumor volumes between groups. The grouping day was defined as day 0. After the start of dosing, the body weight and tumor size of the mice were determined twice weekly, and mice were dosed once weekly for three doses. The clinical symptoms observed during the experiment were recorded.Tumor volume was calculated using the following formula: tumor volume (mm3) = 1 / 2 χ (ax b2) (where a represented the long diameter and b represented the short diameter).

[0231] As shown in FIG. 9, at day 35 post-dose, compared with the control group (MAB20) (ICT of -28.31%), MAB20-LP62 (DAR4) (8 mg / kg) and MAB20-LP62 (DAR8) (8 mg / kg) both exhibited certain inhibitory effects on tumors, with ICTs of 14% and 40.9%, respectively. Compared to the other test drugs MAB20-VC-MMAE (DAR4) (3 mg / kg, ICT of -6.79%) and MAB20-GGFG-DXD (DAR8) (3 mg / kg, ICT of -18.00%; 8 mg / kg, ICT of -0.12%), only MAB20-LP62 achieved an inhibitory effect on tumor growth in models with low PDL1 expression. None of the animals showed significant body weight loss during the treatment period. Petition 870250101969, dated 07 / 11 / 2025, page 90 / 312 83 / 89 Example 12. Antitumor effect of the anti-PDLI antibody-drug conjugate in PDX LU6437 xenografted BALB / c nude mice with human non-small cell lung cancer.

[0232] Revived tumor tissue was harvested from tumor-bearing mice of the HuPrime® LU6437 lung cancer xenograft model and cut into tumor blocks with a diameter of 2–3 mm, which were subcutaneously inoculated into the right anterior scapula of naked BALB / c mice. Once the tumor had grown to a volume of approximately 200 mm3, the mice were randomly grouped depending on tumor size, ensuring that each group had a similar tumor volume. The average volume was 253.70 mm3 in the actual groups. The grouping day was defined as day 0. After the start of dosing, mice were dosed once weekly for three doses, and body weight and tumor size of the mice were measured twice weekly. Clinical symptoms observed during the experiment were recorded.Tumor volume was calculated using the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0233] It should be noted that the preliminary pre-experiment had shown severely lethal toxicity of SGN-PDL1V at a dose of 8 mg / kg in mice. For ethical considerations, the experimental group was not defined in the experimental design.

[0234] As shown in FIG. 10, in the PDX model of human non-small cell lung cancer resistant to anti-PD1 monoclonal antibodies LU6437, MAB20-LP62 at 1 mg / kg (day 21, ICT of -0.16%), 3 mg / kg (day 21, ICT of 43.23%) and 8 mg / kg (day 21, ICT of 106.85%) all exhibited better tumor-inhibiting effects than the control molecule SGN-PDL1V (1 mg / kg, day 21, ICT of -15.17%; 3 mg / kg, day 21, ICT of 24.11%). MAB20-LP62 at 8 mg / kg demonstrated the strongest tumor-inhibiting effect. None of the animals showed significant body weight loss over the treatment period. Petition 870250101969, dated 07 / 11 / 2025, page 91 / 312 84 / 89 Example 13. Antitumor effect of the anti-PDLI antibody-drug conjugate in PDX LD1-0011-200617 xenografted NU / NU mice with human PDLI1-positive liver cancer

[0235] A human-derived liver cancer model LD1-0011-200617 was revived in NCG mice. Once the tumor had grown to 500–800 mm3, the tumor tissue was surgically excised aseptically, with non-tumor and necrotic tissues removed. The tumor tissue was removed and cut uniformly into tissue blocks (approximately 30–60 mg) of approximately 3 mm × 3 mm × 3 mm in size, which were then inoculated subcutaneously into the right side of NU / NU mice. Once the mean tumor volume of the mice for grouping reached 155.24 mm3, the mice were randomly grouped according to tumor volume size, ensuring similar tumor volumes between groups. The grouping day was defined as day 0. After the start of dosing, the body weight and tumor size of the mice were determined twice a week, and the mice were dosed once a week, for three doses.The clinical symptoms observed during the experiment were recorded. The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0236] As shown in FIG. 11, in the PDX model of PDL1-positive liver cancer LD1-0011-200617, the ICT of MAB20 at 10 mg / kg was 30.3% on day 21 post-treatment. In contrast, MAB20-LP62 (DAR8) exhibited dose-dependent tumor-inhibiting effects at both doses of 3 mg / kg (day 21, ICT of 75.24%) and 10 mg / kg (day 21, ICT of 89.51%). The higher dose of MAB20-LP62 (DAR8) demonstrated the strongest tumor-inhibiting effect. None of the animals showed significant body weight loss over the treatment period. Example 14. Antitumor effect of anti-PDL1 antibody-drug conjugate in PDX LD1-2023-411020 xenografted NCG mice with human PD1-positive squamous cell carcinoma of the head and neck. Petition 870250101969, dated 07 / 11 / 2025, p. 92 / 312 85 / 89

[0237] A human-derived LD1-2023-411020 model of PDL1-positive squamous cell carcinoma of the head and neck was revived in NCG mice. Once the tumor had grown to 500–800 mm3, the tumor tissue was surgically excised aseptically, with non-tumor and necrotic tissues removed. The tumor tissue was removed and cut uniformly into tissue blocks (approximately 20–30 mg) of approximately 3 mm × 3 mm × 3 mm in size, which were then inoculated subcutaneously into the right side of NCG mice. Once the mean tumor volume of the mice for grouping reached 138.88 mm3, the mice were randomly grouped according to tumor volume size, ensuring similar tumor volumes between groups. The grouping day was defined as day 0.After the start of dosing, the body weight and tumor size of the mice were determined twice a week, and the mice were dosed once a week, for three doses. The clinical symptoms observed during the experiment were recorded. The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0238] As shown in FIG. 12, in the PDX LD1-2023-411020 model of human PD1-positive squamous cell carcinoma of the head and neck resistant to anti-PD1 monoclonal antibodies, MAB20 at 10 mg / kg did not exhibit a tumor inhibitory effect (day 28, ICT of -34.46%) and the free-loading drug A1.3 also did not exhibit a tumor inhibitory effect (day 28, ICT of -8.74%); However, MAB20-LP62 (DAR8) at the same dose (day 28, ICT of 102.31%) exhibited a strong tumor-inhibiting effect.None of the animals showed significant loss of body weight throughout the treatment period. Example 15. Antitumor effect of the anti-PDLI antibody-drug conjugate in PDX LD1-0010-200614 xenografted nude mice with human PD1-positive cervical cancer

[0239] A human-derived LD1-0010-200614 model of PDL1-positive cervical cancer was revived in Balb / c nude mice. Once having the tumor Petition 870250101969, dated 07 / 11 / 2025, page 93 / 312 86 / 89 grown to 500–800 mm3, the tumor tissue was surgically excised aseptically, with non-tumor and necrotic tissues removed. The tumor tissue was removed and cut uniformly into tissue blocks (approximately 25–35 mg) of approximately 3 mm x 3 mm x 3 mm in size, which were then inoculated subcutaneously into the right side of naked Balb / c mice. Once the mean tumor volume of the mice for grouping reached 146.74 mm3, the mice were randomly grouped according to tumor volume size, ensuring similar tumor volumes between groups. The grouping day was defined as day 0. After the start of dosing, the body weight and tumor size of the mice were determined twice weekly, and the mice were dosed once weekly for three doses. Clinical symptoms observed during the experiment were recorded.The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0240] As shown in FIG. 13, in the PDX LD1-0010-200614 model of human PD1-positive cervical cancer, MAB20 at 10 mg / kg (day 35, ICT 67.38%) exhibited a moderate tumor inhibitory effect and the freely loaded drug A1.3 exhibited a moderate tumor inhibitory effect (day 35, ICT 56.5%); however, MAB20LP62 (DAR8) at the same dose (day 35, ICT 109.33%) exhibited a strong tumor inhibitory effect. None of the animals showed significant body weight loss over the treatment period. Example 16. Antitumor effect of the anti-PDLI antibody-drug conjugate in PDX LD1-0015-362448 xenografted nude mice with human PD1-positive esophageal squamous cell carcinoma

[0241] A human-derived PDL1-positive LD1-0015-362448 model of esophageal squamous cell carcinoma was revived in Balb / c nude mice. Once the tumor had grown to 500–800 mm3, the tumor tissue was surgically excised aseptically, with non-tumor and necrotic tissues removed. The tumor tissue was then uniformly removed and sectioned. Petition 870250101969, dated 07 / 11 / 2025, page 94 / 312 87 / 89 in tissue blocks (approximately 25 to 35 mg) of approximately 3 mm χ 3 mm χ 3 mm in size, which were then inoculated subcutaneously on the right side of naked Balb / c mice. Once the mean tumor volume of the mice for grouping reached 140.46 mm3, the mice were randomly grouped according to tumor volume size, ensuring similar tumor volumes between groups. The grouping day was defined as day 0. After the start of dosing, the body weight and tumor size of the mice were determined twice a week, and the mice were dosed once a week, for three doses. The clinical symptoms observed during the experiment were recorded. The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0242] As shown in FIG.In the PDX LD1-0015-362448 model of human PD1-positive esophageal squamous cell carcinoma, MAB20-LP62 (DAR8) at 10 mg / kg (day 45, ICT of 92.02%) exhibited a strong tumor-inhibiting effect. None of the animals showed significant body weight loss over the treatment period. Example 17. Antitumor effect of the anti-PDLI antibody-drug conjugate in PDX LD1-0017-200636 xenografted NU / NU mice with human PD1-positive gastric cancer

[0243] A human-derived LD1-0017-200636 model of PDL1-positive gastric cancer was revived in NU / NU mice. Once the tumor had grown to 500–800 mm3, the tumor tissue was surgically excised aseptically, with non-tumor and necrotic tissues removed. The tumor tissue was removed and cut uniformly into tissue blocks (approximately 30–60 mg) of approximately 3 mm × 3 mm × 3 mm in size, which were then inoculated subcutaneously into the right side of NU / NU mice. Once the mean tumor volume of the mice for grouping reached 138.70 mm3, the mice were randomly grouped according to tumor volume size, ensuring similar tumor volumes between groups. Petition 870250101969, dated 07 / 11 / 2025, page 95 / 312 88 / 89 The grouping day was defined as day 0. After the start of dosing, the body weight and tumor size of the mice were determined twice a week, and the mice were dosed once a week, for three doses. The clinical symptoms observed during the experiment were recorded. The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 χ (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0244] As shown in FIG. 15, in the PDX LD1-0017-200636 human PDLI-positive gastric cancer model, MAB20 at 10 mg / kg showed an ICT of 14.89% on day 21 and the free loaded drug A1.3 showed an ICT of 34.12%; however, MAB20-LP62 (DAR8) at 10 mg / kg (day 21, ICT of 108.18%) exhibited a strong tumor inhibitory effect. None of the animals showed significant body weight loss over the treatment period. Example 18. Antitumor effect of the anti-PDLI antibody-drug conjugate in PDX LD1-2013-362125 xenografted NU / NU mice with human PDLI1-positive colorectal cancer.

[0245] A human-derived LD1-2013-362125 model of PDL1-positive colorectal cancer was revived in NU / NU mice. Once the tumor had grown to 500–800 mm3, the tumor tissue was surgically excised aseptically, with non-tumor and necrotic tissues removed. The tumor tissue was removed and cut uniformly into tissue blocks (approximately 25–35 mg) of approximately 3 mm × 3 mm × 3 mm in size, which were then inoculated subcutaneously into the right side of NU / NU mice. Once the mean tumor volume of the mice for grouping reached 156.99 mm3, the mice were randomly grouped according to tumor volume size, ensuring similar tumor volumes between groups. The grouping day was defined as day 0.After the start of dosing, the body weight and tumor size of the mice were determined twice a week, and the mice were dosed once a week for three doses. The clinical symptoms observed during the experiment were recorded. Petition 870250101969, dated 07 / 11 / 2025, page 96 / 312 89 / 89 The tumor volume was calculated according to the following formula: tumor volume (mm3) = 1 / 2 x (a χ b2) (where a represented the long diameter and b represented the short diameter).

[0246] As shown in FIG. 16, in the PDX LD1-2013-362125 human colorectal cancer model PD1-positive, MAB20 at 10 mg / kg showed an ICT of 50.27% on day 31 and the free loaded drug A1.3 showed an ICT of 37.16%; however, MAB20-LP62 (DAR8) at the same dose (ICT of 101.59%) exhibited a strong tumor inhibitory effect. None of the animals showed significant body weight loss over the treatment period.

[0247] In addition to the various embodiments illustrated and claimed, the disclosed subject matter also refers to other embodiments that have other combinations of the features disclosed and claimed in this document. As such, the particular features presented in this document may be combined with each other in other ways within the scope of the disclosed subject matter, so that the disclosed subject matter includes any suitable combination of the features disclosed in this document. The foregoing description of specific embodiments of the disclosed subject matter was presented for illustrative and descriptive purposes. The above description is not intended to be exhaustive or to limit the disclosed subject matter to those disclosed embodiments.

[0248] It will be evident to those skilled in the art that various modifications and variations can be made to the compositions and methods of the disclosed subject matter without departing from the spirit or scope of the disclosed subject matter. Thus, it is intended that the disclosed subject matter includes modifications and variations that are within the scope of the appended claims and their equivalents.

[0249] Several publications, patents and patent applications are cited in this document, the contents of which are incorporated herein by way of reference in their entirety. Petition 870250101969, dated 07 / 11 / 2025, page 97 / 312

Claims

1 / 15 CLAIMS 1. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, the antibody-drug conjugate being characterized by having a structure represented by formula (I): TP-[L1-L2-L3-D]k (I) wherein TP is a targeting moiety that selectively binds to or recognizes PDL1; L1 is an extension unit connecting TP and L2; L2 is an optional amino acid residue or a short peptide consisting of 2 to 10 amino acid residues; L3 is a spacer element; D is a biologically active molecule; ek represents any numerical value between 0.1 and 10.

0.

2. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to claim 1, characterized in that the TP is an antigen-binding antibody or fragment thereof.

3. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to claim 2, characterized in that the antigen-binding fragment is selected from a full-length immunoglobulin, a single-chain Fv fragment (scFv), a Fab fragment, a Fab' fragment, F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), (dsFv)2, an Fv-Fc fusion, an scFv-Fc fusion, an scFv-Fv fusion, a diabody, a tribody, a tetrabody, or any combination thereof. Petition 870250101969, dated 11 / 07 / 2025, page 98 / 312 2 / 15 4. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the prodrug is a humanized antibody or a fragment thereof that binds to the antigen.

5. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP comprises a variable heavy chain region (VH) and a variable light chain region (VL), wherein the variable heavy chain region (VH) comprises the complementarity-determining region of heavy chain 1 (HCDR1), HCDR2 and HCDR3 contained in SEQ ID NO: 7, and the variable light chain region (VL) comprises the complementarity-determining region of light chain 1 (LCDR1), LCDR2 and LCDR3 contained in SEQ ID NO:

8.

6. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to claim 5, characterized in that the amino acid sequence of HCDR1 is SEQ ID NO: 1, the amino acid sequence of HCDR2 is SEQ ID NO: 2 and the amino acid sequence of HCDR3 is SEQ ID NO: 3; and the amino acid sequence of LCDR1 is SEQ ID NO: 4, the amino acid sequence of LCDR2 is SEQ ID NO: 5 and the amino acid sequence of LCDR3 is SEQ ID NO:

6.

7. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP comprises a human IgG Fc sequence.

8. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the IgG is selected from IgG1, IgG2, IgG3 and IgG4.

9. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP comprises a variable heavy chain (VH) region and the amino acid sequence of the variable heavy chain (VH) region has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO:

7.

10. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP comprises a variable light chain (VL) region and the amino acid sequence of the variable light chain (VL) region has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO:

8.

11. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP comprises a heavy chain (HC) and the amino acid sequence of the heavy chain (HC) has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO:

9. Petition 870250101969, dated 07 / 11 / 2025, p. 100 / 312 4 / 15 12. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP comprises a light chain (LC) and the amino acid sequence of the light chain (LC) has at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% identity with SEQ ID NO:

10.

13. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that TP is a multispecific antibody.

14. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the TP is an afucosylated antibody.

15. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the Fc region comprises a C-terminal lysine.

16. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that the Fc region comprises a deletion of the C-terminal lysine.

17. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that L1 is selected from where L1 is connected to TP at position a by means of an S atom and L2 at position b, m is any integer between 1 and 10, n is any integer between 1 and 10, and X and Y are each independently C, O, S or N.

18. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that L1 is where m is selected from 1, 2, 3, 4 or 5, wherein L1 is connected to TP at position a by means of an S atom and to L2 at position b.

19. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that L1 is connected to TP at position a by means of an S atom and L2 at position b.

20. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or pharmaceutically acceptable salt solvate, according to any of the preceding claims, characterized in that L2 is selected from wherein L2 is connected to L1 at position c and L3 at position d.

21. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that L2 is connected to L1 at the cea position and L3 at the d position.

22. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that L3 is a single linkage or a group selected from: Petition 870250101969, dated 07 / 11 / 2025, page 103 / 312 7 / 15 wherein L3 is connected to L2 at the ea position and D at the f position, Z is selected from hydrogen, halogen, C1-C20 alkyl, C1-C20 haloalkyl, cyano, sulfo, carboxyl, C1-C20 alkoxy, unsaturated C2-C10 alkyl, a natural amino acid, a non-natural amino acid and a short peptide consisting of the above amino acids.

23. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that Z is selected from: wherein Z is connected to the remainder of L3 at the g position, z1 to z9 are each independently an integer between 0 and 10 and T is NH2 or OH.

24. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that D is a cytotoxic agent.

25. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that D is selected from OH O wherein D is connected to L3 at the h position.

26. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, the antibody-drug conjugate being characterized by being selected from: Petition 870250101969, dated 07 / 11 / 2025, page 105 / 312 9 / 15 (A-1) (A-2) (A-3) (A-4) Petition 870250101969, dated 07 / 11 / 2025, page 106 / 312 10 / 15 Petition 870250101969, dated 07 / 11 / 2025, page 107 / 312 11 / 15 wherein Ac represents the antibody or antigen-binding fragment thereof.

27. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any of the preceding claims, characterized in that k is about 4.0 to about 8.0, preferably k is about 4.0, about 6.0 or about 8.

0.

28. Pharmaceutical composition characterized by comprising the antibody-drug conjugate, the prodrug, the pharmaceutically acceptable salt or solvate thereof, or the solvate of the pharmaceutically acceptable salt as defined in any of claims 1 to 27, and optionally a pharmaceutically acceptable vehicle, diluent or excipient.

29. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any one of claims 1 to 27, or pharmaceutical composition, according to claim 28, characterized in that they are intended for use as a drug.

30. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, according to any one of claims 1 to 27, or pharmaceutical composition, according to claim 28, characterized in that they are intended for use in the treatment or prevention of a tumor or cancer.

31. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, or pharmaceutical composition for use in the treatment or prevention of a tumor or cancer, according to claim 30, characterized in that the tumor or cancer is a PDL1-related tumor or cancer.

32. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, or pharmaceutical composition for use in the treatment or prevention of a tumor or cancer, according to claim 30, characterized in that the tumor or cancer is selected from melanoma, lung cancer, head and neck cancer, breast cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, bladder cancer, esophageal cancer, kidney cancer, prostate cancer, pancreatic cancer and glioma.

33. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, or pharmaceutical composition for use in the treatment or prevention of a tumor or cancer, according to claim 32, characterized in that the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

34. Antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt, or pharmaceutical composition for use in the treatment or prevention of a tumor or cancer, according to claim 32, characterized in that the breast cancer is triple-negative breast cancer (TNBC).

35. Article of manufacture or kit characterized by comprising the antibody-drug conjugate, the prodrug, the pharmaceutically acceptable salt or solvate thereof, or the solvate of the pharmaceutically acceptable salt as defined in any of claims 1 to 27 or the pharmaceutical composition as defined in claim 28, and instructions for use.

36. A method for preventing or treating a tumor or cancer, characterized by comprising administering to a subject in need thereof a prophylactic or therapeutically effective amount of the antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt as defined in any one of claims 1 to 27 or of the pharmaceutical composition as defined in claim 28.

37. Method according to claim 36, characterized in that the tumor or cancer is a tumor or cancer related to PDL1 expression.

38. Method according to claim 36, characterized in that the PDL1 expression-related tumor or cancer is selected from melanoma, lung cancer, head and neck cancer, breast cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, bladder cancer, esophageal cancer, kidney cancer, prostate cancer, pancreatic cancer, and glioma. Petition 870250101969, dated 07 / 11 / 2025, pp. 110 / 312 14 / 15 39. Method according to claim 38, characterized in that the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

40. Method, according to claim 38, characterized in that the breast cancer is triple-negative breast cancer (TNBC).

41. Method, according to any one of claims 36 to 40, the method being characterized by comprising administering to the subject an additional therapeutic agent selected from among an antitumor agent, a chemotherapeutic agent, a growth inhibitor and a cytotoxic agent.

42. Method, according to any one of claims 36 to 41, the method being characterized by comprising the additional administration of radiotherapy to the subject.

43. Use of the antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt as defined in any of claims 1 to 27 or of the pharmaceutical composition as defined in claim 28, characterized in that it is intended for the preparation of a medicament for use in the prevention or treatment of a tumor or cancer.

44. Use of the antibody-drug conjugate, prodrug, pharmaceutically acceptable salt or solvate thereof, or solvate of the pharmaceutically acceptable salt as defined in any of claims 1 to 27 or of the pharmaceutical composition as defined in claim 28 in combination with an additional therapeutic agent, characterized in that it is intended for the preparation of a medicament for use in the prevention or treatment of a tumor or cancer.

45. Use, according to any of claims 43 and 44, characterized by the tumor or cancer being a tumor or cancer related to the expression PDL1.

46. ​​Use, according to claim 45, characterized in that the PDL1 expression-related tumor or cancer is selected from melanoma, lung cancer, head and neck cancer, breast cancer, ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, bladder cancer, esophageal cancer, kidney cancer, prostate cancer, pancreatic cancer and glioma.

47. Use, according to claim 46, characterized in that the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

48. Use, according to claim 46, characterized in that the breast cancer is triple-negative breast cancer (TNBC).

49. Use, according to any one of claims 44 to 48, characterized in that the additional therapeutic agent is selected from among an antitumor agent, a chemotherapeutic agent, a growth inhibitor, and a cytotoxic agent. Petition 870250101969, dated 07 / 11 / 2025, pp. 112 / 312